PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 311/30, 221/04, 335/06, A61K 31/35, 31/47, 31/38 — A1

(11) International Publication Number: **WO 98/25916**

(43) International Publication Date: 18 June 1998 (18.06.98)

(21) International Application Number: PCT/KR97/00265

(22) International Filing Date: 13 December 1997 (13.12.97)

(30) Priority Data:
1996/65301 13 December 1996 (13.12.96) KR
1997/26915 24 June 1997 (24.06.97) KR

(71) Applicant *(for all designated States except US)*: C & C RESEARCH LABORATORIES [KR/KR]; 146–141, Annyung–ri, Taean–ub, Hwasung–gun, Kyunggi–do 445–970 (KR).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: JO, Jae, Chon [KR/KR]; Samhwan Apartment, #1–810, Kuwoon–dong, Kwonsun–gu, Suwon–shi, Kyunggi–do 441–340 (KR). PARK, Sung, Dae [KR/KR]; Jamwon Family Apartment, #1–1006, Jamwon–dong, Seocho–gu, Seoul 137–030 (KR). LIM, Hyun, Suk [KR/KR]; Jugong Apartment, #525–503, Maetan–dong, Paldal–gu, Suwon–shi, Kyunggi–do 442–370 (KR). KIM, Ju, Su [KR/KR]; 777–1, Bono–dong, Ansan–shi, Kyunggi–do 425–180 (KR). KIM, Sung, Jin [KR/KR]; 918–7, Juan 6–dong, Nam–gu, Inchun 402–206 (KR). MORIKAWA, Kazumi [JP/JP]; 5–2, Higashi–Icchouda, Mishima–city, Sizuoka 411 (JP). KANBE, Yoshitake [JP/JP]; 1–9–10–301, Higashi–Tanaka, Gotemba–city, Shizuoka 412 (JP). NISHIMOTO, Masahiro [JP/JP]; 7–35–305, Ohmiya–cho 3–chome, Mishima–city, Sizuoka 411 (JP). KIM, Myung–Hwa [KR/KR]; 25–3–303, Hagiwara, Gotemba–city, Sizuoka 412 (KR).

(74) Agents: CHOI, Kyu, Pal et al.; 824–20, Yeoksam–dong, Kangnam–ku, Seoul 135–080 (KR).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

AG

(54) Title: NOVEL BENZOPYRAN DERIVATIVES

(57) Abstract

The present invention relates to a novel benzopyran derivative having anti–estrogenic activity. More specifically, the present invention relates to a novel benzopyran derivative represented by formula (I) and pharmaceutically acceptable salt thereof, in which ═══ represents a single bond or a double bond; R_1 and R_2 independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl; R_3 represents hydrogen, lower alkyl or halogeno lower alkyl, provided that when ═══ represents a double bond, R_3 is not present; R_4 represents hydrogen or lower alkyl; A represents a group of formula (a), (b), (c) or (d); R_5, R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or R_6 and R_7 together with nitrogen atom to which they are bound can form a 4– to 8–membered heterocyclic ring which can be substituted with R_5; X represents O, S or NR_8, wherein R_8 represents hydrogen or lower alkyl; m denotes an integer of 2 to 15; n denotes an integer of 0 to 2; and p denotes an integer of 0 to 4, and to a process for preparation thereof and a pharmaceutical composition having anti–estrogenic activity which contains the compound (I) as an active component.



(I)



(a)



(b)



(c)



(d)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NOVEL BENZOPYRAN DERIVATIVES

TECHNICAL FIELD

The present invention relates to a novel benzopyran derivative having anti-estrogenic activity. More specifically, the present invention relates to a novel benzopyran derivative represented by formula (I):



(I)

and pharmaceutically acceptable salt thereof, in which

$\overline{\overline{\cdots}}$ represents a single bond or a double bond;

R_1 and R_2 independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl;

R_3 represents hydrogen, lower alkyl or halogeno lower alkyl, provided that when $\overline{\overline{\cdots}}$ represents a double bond, R_3 is not present;

R_4 represents hydrogen or lower alkyl;

A represents a group of formula (a), (b), (c) or (d);



(a)

(b)

(c)

(d)

R_5, R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5;

X represents O, S or NR_8, wherein R_8 represents hydrogen or lower alkyl;

m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and

p denotes an integer of 0 to 4,

and to a process for preparation thereof and a pharmaceutical composition having anti-estrogenic activity which contains the compound (I) as an active component.

BACKGROUND ART

In treating diseases caused by the abnormal tissue growth depending on a certain sexual steroidal hormone such as estrogen, it is very important to significantly inhibit, if possible, to completely remove the effect induced by said sexual steroidal hormone. For this purpose, it is desirable to block the receptor site which can be stimulated by sexual steroidal hormone and further, to reduce the level of sexual steroidal hormone capable of acting on said receptor site. For instance, as a substitution or combined therapy, administration of anti-estrogenic agents to limit the production of estrogen to the amount less than required to activate the receptor site may be used. However, prior methods for blocking the estrogen production could not sufficiently inhibit the effect induced through estrogen receptor. Practically, even when estrogen is completely absent, some of the receptors may be activated. Accordingly, it was considered that antagonists for estrogen can provide better therapeutic effect in comparison to the method for blocking only the production of sexual steroidal hormone. Thus, numerous anti-estrogenic compounds have been developed. For example, many patent publications including U.S. Patent Specifications 4,760,061, 4,732,912, 4,904,661 and 5,395,842 and WO 96/22092, etc. disclose various anti-estrogenic compounds.

However, prior antagonists have sometimes insufficient affinity to the receptors. In some cases, moreover, they can combine to the receptor but act themselves as agonists, and therefore, activate rather than block the receptor. For example, Tamoxifen has been most widely used as an anti- estrogenic agent. However, it has a disadvantage that it exhibits estrogenic activity in some organs (see, M. Harper and A. Walpole, J. Reprod. Fertil., 1967, 13, 101). Therefore, it is required to develop the anti-estrogenic compound which has substantially or completely no agonistic effect and can effectively block the estrogenic receptor.

In addition, it has been known that 7α-substituted derivatives of estradiol, for example, 7α-$(CH_2)_{10}CONMeBu$ derivative, exhibit anti-estrogenic activity (see, EP Appl. 0138504, USP 4,659,516). Further, estradiol derivative having $-(CH_2)_9SOC_5H_6F_5$ substituent has also been disclosed (see, Wakeling et al., Cancer Res., 1991, 51, 3867) as steroidal anti-estrogen without agonistic effect.

Non-steroidal anti-estrogenic drug without agonistic effect has been first reported by Wakeling et al. in 1987 (see, A. Wakeling and J. Bowler, J. Endocrinol., 1987, 112, R7). Meanwhile, U.S. Patent Sepcification 4,904,661 (ICI, Great Britain) discloses a phenol derivative having anti-estrogenic activity. This phenol derivative generally has a naphthalene structure and includes, typically, the following compounds:







As other non-steroidal anti-estrogenic compounds, WO 93/10741 discloses benzopyran derivatives having aminoethoxyphenyl substituent (Endorecherche), of which the typical compound is EM-343 having the following structure:



Accordingly, the present inventors have researched the anti-estrogenic activity of compounds having various structures. As a result, we have identified that the benzopyran derivatives represented by formula (I), as defined above, can exhibit a good anti-estrogenic activity without agonistic activity, to be expected no undesirable side effect and thus, completed the present invention.

DISCLOSURE OF THE INVENTION

Therefore, the present invention relates to a novel benzopyran derivative represented by formula (I):



(I)

and pharmaceutically acceptable salt thereof, in which

⎓ represents a single bond or a double bond;

R_1 and R_2 independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl;

R_3 represents hydrogen, lower alkyl or halogeno lower alkyl, provided that when ⎓ represents a double bond, R_3 is not present;

R_4 represents hydrogen or lower alkyl;

A represents a group of formula (a), (b), (c) or (d);



(a)



(b)



(c)



(d)

R_5, R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5;

X represents O, S or NR_8, wherein R_8 represents hydrogen or lower alkyl;

m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and

p denotes an integer of 0 to 4.

In addition, the present invention also relates to a process for preparing the benzopyran derivative of formula (I).

Further, the present invention relates to a pharmaceutical composition having anti-estrogenic activity, which contains the compound of formula (I) as an active component.

BEST MODE FOR CARRYING OUT THE INVENTION

In the present specification, the term "lower alkyl" denotes straight or branched saturated hydrocarbon radicals having 1 to 6, preferably 1 to 4, carbon atoms; the term "halogeno lower alkyl" denotes straight or branched saturated hydrocarbon radicals having 1 to 6, preferably 1 to 4, carbon atoms and 1 to 9, preferably 1 to 5, halogen atoms such as fluorine, chlorine, bromine, etc, preferably fluorine atom; the term "alkyl" denotes straight or branched saturated hydrocarbon radicals having 1 to 10, preferably 1 to 6, carbon atoms including lower alkyl as defined above; and the term "alkenyl" denotes straight or branched hydrocarbon radicals having 2 to 10, preferably 2 to 6, carbon atoms and one or more double bond(s). Further, the term "4- to 8-membered heterocyclic ring" denotes saturated or unsaturated heteromonocyclic ring which can contain 1 to 4 nitrogen atoms and includes, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, pyridazinyl, triazolyl, tetrazolyl, piperazinyl, piperidino, pyrrolidinyl, imidazolidinyl, etc.

In the compound of formula (I) according to the present invention, preferably R_1 and R_2 independently of one another represent hydrogen, hydroxy or OR wherein R represents acyl or alkyl, R_3 represents hydrogen, C_1-C_4 lower alkyl or halogeno-C_1-C_4 lower alkyl, R_4 represents hydrogen or C_1-C_4 lower alkyl, A represents a group of formula (a), (b), (c) or (d), R_5, R_6 and R_7 independently of one another represent hydrogen, C_1-C_6 alkyl, halogeno-C_1-C_6 alkyl, C_2-C_6 alkenyl or halogeno-C_2-C_6 alkenyl, or R_6 and R_7 together with

nitrogen atom to which they are bound can form a 5- to 6-membered heterocyclic ring which can contain 1 to 2 nitrogen atoms and can be substituted with halogeno-C_1-C_6 alkyl, X represents O, S or NR_8, wherein R_8 represents hydrogen or C_1-C_4 lower alkyl, m denotes an integer of 4 to 12, n denotes an integer of 0 to 2 and p denotes an integer of 1 to 3.

Particularly preferable compound of formula (I) according to the present invention includes those wherein R_1 and R_2 independently of one another represent hydrogen or hydroxy, R_3 represents hydrogen or C_1-C_2 lower alkyl, R_4 represents hydrogen or C_1-C_2 lower alkyl, A represents a group of formula (a), (b), (c) or (d), R_5, R_6 and R_7 independently of one another represents hydrogen, C_1-C_6 alkyl or halogeno-C_1-C_6 alkyl, or R_6 and R_7 together with nitrogen atom to which they are bound can form piperazinyl or piperidino group which can be substituted with halogeno-C_1-C_6 alkyl, X represents O or S, m denotes an integer of 4 to 12, n denotes an integer of 0 to 2 and p denotes an integer of 2.

As specific example of the compound of formula (I) according to the present invention, the following compounds can be mentioned:

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-2,3-dihydro-4H-benzopyran;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylthio)octyl]-2,3-dihydro-4H-benzopyran;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfinyl)octyl]-2,3-dihydro-4H-benzopyran;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfonyl)nonyl]-2,3-dihydro-4H-benzopyran;
7-hydroxy-3-(4-hydroxyphenyl)-4-[4-(5-(4,4,5,5,5-pentafluoropentylthio)pentyloxy)-phenyl]-2H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-thiochroman;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylsulfinyl)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylsulfonyl)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(2-piperidinoethylthio)-nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(2-piperidinoethylsulfinyl)-nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(5-(4,4,5,5,5-pentafluoropentylthio)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(5-(4,4,5,5,5-pentafluoropentylsulfinyl)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(piperidinoethyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentyloxy)phenyl]thiochroman;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(4-piperidinobutyloxy)-phenyl]thiochroman or its hydrochloride;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{4-[2-(4-(4,4,5,5,5-pentafluoropentyl)piperazino)ethyloxy]phenyl}thiochroman dihydrochloride;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfinyl)octyl]thiochroman;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[10-(4,4,5,5,5-pentafluoropentylsulfinyl)decyl]thiochroman;

(3RS,4RS)-7-hydroxy-3-phenyl-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]thiochroman;

(3RS,4RS)-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]thiochroman;

(3RS,4RS)-7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-(9-pentylthiononyl)thiochroman;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentylthiononyl)thiochroman;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentylsulfinynonyl)thiochroman;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman; and

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman.

The present invention also provides a process for preparing the compound of formula (I) as defined above. According to the present invention, the compound of formula (I) can be prepared by a method depicted in anyone of the following reaction schemes I, II, III, IV, V, VI and VII.

Reaction Scheme I (Process 1)



(VIII) (VII)



(VIA) (VIB)



(VIC) (IV)



(II)



(Ia) (Ib)

Reaction Scheme II (Process 2)









(Id)

Reaction Scheme III (Process 3)



Reaction Scheme IV (Process 4)



Reaction Scheme V (Process 5)



Reaction Scheme VI (Process 6)



Reaction Scheme VII (Process 7)



In the above reaction schemes I, II, III, IV, V, VI and VII

, R, R_1 to R_8, X, m and n are defined as in formula (I),

R_9 represents methyl or tolyl,

P represents hydrogen or hydroxy protected by a conventional hydroxy-protecting group such as methoxymethyl or t-butyldimthylsilyl,

W represents R_5 or  , wherein R_5, R_6, R_7 and p are defined as in formula (I),

Z represents halogen,
Y represents halogen or hydroxy,
q denotes an integer of m-2, and
TBS denotes t-butyldimethylsilyl group and TMS denotes trimethylsilyl group.

Hereinafter, the process of the present invention will be more specifically explained.

Process 1

According to the process 1 of the present invention for preparing the compound of formula (I), in the first reaction step a compound of formula (VIII) is reacted with a compound of formula (IX) to produce a compound of formula (VII). This reaction can preferably be carried out in the presence of a solvent. Although any of organic solvents which do not adversely affect the reaction can be used as the solvent in this reaction, the reaction is preferably carried out in the solvent such as tetrahydrofuran, ethyl ether, dioxane, hexane, etc., with tetrahydrofuran being particularly preferable. The reaction is preferably conducted under anhydrous condition. The reaction temperature is not specifically limited and the reaction can be generally carried out under cooling to warming, preferably at room temperature.

In the second reaction step, the compound of formula (VII) produced in the first reaction step is reduced to produce a compound of formula (VIC). This reduction can be practiced by means of any of conventional reduction methods, for example, using a combination of metal and organic or inorganic acid or by catalytic reduction in the presence of a metallic catalyst. This reaction is actually conducted in the manner that the compound (VII) is reduced with sodium cyanoborohydride and zinc iodide to produce a compound of formula (VIA) and then the compound of formula (VIA) is reduced using Pd/C to produce a compound of formula (VIB) which is then treated with pyridinium p-toulenesulfonate (PPTS) to obtain the compound (VIC).

The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, ethyl acetate, methanol, ethanol, etc., with ethyl acetate being particularly preferable. The reaction temperature is not specifically limited and the reaction can be generally carried out under cooling to warming.

In the third reaction step, the compound of formula (VI) produced in the second reaction step is reacted with a compound of formula (V) to produce a compound of formula (IV). This reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, pyridine, dichloromethane, ethyl acetate, tetrahydrofuran, ethyl ether, chloroform, etc., with pyridine and dichloromethane being particularly preferable. The reaction temperature is not specifically limited and the reaction can be generally carried out under cooling to warming.

In the fourth reaction step, the compound of formula (IV) produced in the third reaction step is reacted with a compound of formula (III) to produce a compound of formula (II). The reaction is preferably carried out in the presence of a base. The base which can be preferably used for this purpose includes, for example, sodium hydroxide, sodium methoxide, potassium hydroxide, sodium ethoxide, etc., with sodium hydroxide being particularly preferable. The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, methanol, ethanol, tetrahydrofuran, dioxane, etc., with methanol being particularly preferable.

In the fifth reaction step, the compound of formula (II) produced in the fourth reaction step wherein P represents protected hydroxy group, is subsequently deprotected to produce a compound of formula (Ia). The deprotection can be conducted according to a conventional deprotection method

such as hydrolysis in the presence of acid or base, reduction, and the like.

If desired, in the sixth reaction step, the compound of formula (Ia) thus produced is alkylated or esterified according to a conventional method to produce a compound of formula (Ib) wherein R represents acyl or alkyl.

In addition, the compound of formula (I), wherein n is 0, produced according to the process 1 can be converted into the corresponding sulfinyl or sulfonyl compound wherein n is 1 or 2 according to a conventional oxidation method. As the oxidizing agent suitable for this reaction, for example, sodium periodate ($NaIO_4$), metachloroperbenzoic acid, hydrogen peroxide, oxone, etc. can be preferably used. The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, methanol, dioxane, water, ethanol, tetrahydrofuran, etc.

The desired compound produced in this process can be separated and purified according to a conventional method such as column chromatography, recrystallization, etc.

Process 2

According to the process 2 of the present invention for preparing the compound of formula (I), in the first reaction step the compound of formula (VIII) is reacted with a compound of formula (XIV) to produce a compound of formula (XIII). This reaction is carried out in the presence of magnesium so that the compound (XIV) can first be reacted with magnesium to form a Grignard reagent and the resulting Grignard reagent is then reacted with the compound of formula (VIII). The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes tetrahydrofuran, ethyl ether, dioxane, etc. The reaction is preferably conducted under

anhydrous condition. The reaction is generally carried out under cooling, preferably at -78℃ to room temperature.

In the second reaction step, the compound of formula (XIII) produced in the first reaction step is reacted with a compound of formula (XII) to produce a compound of formula (XI). This reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, acetone, methyl ethyl ketone, tetrahydrofuran, ethyl acetate, dioxane, etc. The reaction is generally carried out under reflux.

In view of the reaction efficiency in the next reaction step, if necessary, it may be preferable to convert the compound wherein Y is hydroxy or halogen such as chloro, except iodo, into the compound wherein Y is iodo by reacting with an iodizing agent such as sodium iodide.

In the third reaction step, the compound of formula (XI) produced in the second reaction step is reacted with a compound of formula (IIIa) to produce a compound of formula (X). This reaction is carried out under the same condition as in the fourth reaction step of the process 1.

The compound of formula (X) thus produced is subsequently deprotected to produce a compound of formula (Ic). If desired, the resulting compound of formula (Ic) is then alkylated or esterified to produce a compound of formula (Id). This reaction is carried out under the same condition as in the fifth and sixth reaction steps of the process 1.

In addition, the compound of formula (I), wherein n is 0, produced according to the process 2 can be oxidized according to a conventional method to convert into the corresponding sulfinyl or sulfonyl compound wherein n is 1 or 2, as mentioned in the process 1.

The desired compound produced in this process can be separated and purified according to a conventional method such as column chromatography, recrystallization, etc.

Process 3

According to another process 3 of the present invention for preparing the compound of formula (I), the compound of formula (XI) is reacted with an amino compound of formula (XVI) to produce a compound of formula (XV), which is then deprotected and optionally alkylated or esterified according to the same procedures as the fifth and sixth reaction steps of the process 1 to produce a compound of formulae (Ie) and (If). The reaction between the compound of formula (XI) and the compound of formula (XVI) is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, chloroform, ethyl acetate, dichloromethane, tetrahydrofuran, etc. The reaction temperature is not specifically limited and the reaction can be generally carried out under cooling to warming.

The desired compound produced in this process can be separated and purified according to a conventional method such as column chromatography, recrystallization, etc.

Process 4

According to the process 4 of the present invention for preparing the compound of formula (Ig), in the first reaction step a compound of formula (VIII) is reacted with a compound of formula (XVI) to produce a compound of formula (XVII). This reaction is carried out in the presence of magnesium so that the compound (XVI) can first be reacted with magnesium to form a Grignard reagent and the resulting Grignard reagent is then reacted with the compound of formula (VIII). The reaction is generally carried out in the

presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes tetrahydrofuran, ethyl ether, dioxane, etc. The reaction is preferably conducted under anhydrous condition. The reaction is generally carried out under refluxing temperature.

In the second reaction step, the compound of formula (XVII) produced in the first reaction step is reduced to produce a compound of formula (XVIII). This reaction can be practiced by means of any conventional method, for example, sodium cyanoborohydride, lithium aluminumhydride, etc., with Lewis acid such as zinc iodide, iron (III) chloride, trifluoroborane etherate, etc. The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, dichloromethane, 1,2-dichloroethane, chloroform, etc., with dichloromethane being particularly preferable.

In the third reaction step, the compound of formula (XVIII) produced in the second reaction step is deprotected to produce a compound of formula (XIX). The deprotection can be conducted according to a conventional deprotecting method with tetra-n-butylammonium fluoride, hydrogen chloride, hydrogen fluoride, etc. The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, tetrahydrofuran, ethyl ether, dichloromethane, etc., with tetrahydrofuran being particularly preferable.

In the fourth reaction step, the compound of formula (XIX) produced in the third reaction step is reacted with a compound of formula (XX) to produce a compound of formula (XXI). This reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, dimethylformamide, toluene, 2-butanone, tetrahydrofuran, acetone,

dioxane, etc. The reaction is generally carried out under refluxing in the presence of a base such as potassium carbonate, sodium hydroxide, cesium carbonate, and crown ether.

In the fifth reaction step, the compound of formula (XXI) produced in the fourth reaction step wherein P represents protected hydroxy group, is subsequently deprotected to produce a compound of formula (Ig). The deprotection can be conducted under the same condition as in the fifth reaction step of the process 1.

Process 5

According to the process of the present invention for preparing the compound of formula (XX), in the first reaction step a compound of formula (XXII) is reacted with a compound of formula (XXIII) to produce a compound of formula (XXIV). The reaction is preferably carried out in the presence of a base. The base which can be preferably used for this purpose includes, for example, sodium hydroxide, sodium methoxide, potassium hydroxide, sodium ethoxide, etc., with sodium hydroxide being particularly preferable. The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, methanol, ethanol, tetrahydrofuran, dioxane, etc., with methanol being particularly preferable.

In the second reaction step, the compound of formula (XXIV) produced in the first reaction step is oxidized to produce a compound of formula (XX). As the oxidizing agent suitable for this reaction, for example, sodium periodate ($NaIO_4$), metachloroperbenzoic acid, hydrogen peroxide, oxone, etc. can be preferably used. The reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, methanol, dioxane, water, ethanol, tetrahydrofuran, etc.

Process 6

According to the process 6 of the present invention for preparing the compound of formulae (XXVIII) and (XXIX), in the first reaction step a compound of formula (XXV) is reacted with a compound of formula (XII) to produce a compound of formula (XXVI). This reaction is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, acetone, 2-butanone, tetrahydrofuran, ethyl acetate, dichloromethane, chloroform, etc., with acetone and 2-butanone being particularly preferable. The reaction temperature is not specifically limited and the reaction can be generally carried out under heating.

In the second reaction step, the compound of formula (XXVI) produced in the first reaction step is reacted with an amino compound of formula (XVI) to produce a compound of formula (XXVII), which is then deprotected and optionally alkylated or esterified according to the same procedures as the fifth and sixth reaction steps of the process 1 to produce a compound of formulae (Ia) and (Ib). The reaction between the compound of formula (XXVI) and the compound of formula (XVI) is generally carried out in the presence of a solvent which does not adversely affect the reaction. The solvent which can be preferably used for this purpose includes, for example, ethanol, isopropanol, t-butanol, tetrahydrofuran, dichloromethane, chloroform, etc., with ethanol and isopropanol being particularly preferable. The reaction temperature is not specifically limited and the reaction can be generally carried out under heating.

The desired compound produced in this process can be separated and purified according to a conventional method such as column chromatography, recrystallization, etc.

Process 7

The process 7 depicted in the reaction scheme VII is a method for preparing the chromanon derivative of formula (6) which is the starting compound required for preparing the compound of formula (I) wherein X is S. The specific method and reaction conditions refer to Example 57 described hereinafter.

As stated above, the compound of formula (I) prepared according to the process of the present invention as mentioned above has a good anti-estrogenic activity and, therefore, can be used for treatment of estrogen-related diseases including anovular infertility, breast cancer, endometrial cancer, uterine cancer, ovarian cancer, endometriosis, endometrial fibroma, benign prostate hypertrophy, premature, menstrual disorder, etc.

Therefore, the present invention relates to an anti-estrogenic pharmaceutical composition containing the compound of formula (I) as an active component.

When the anti-estrogenic pharmaceutical composition containing the compound of the present invention as an active component is used for clinical purpose, it can be formulated into a conventional preparation in the pharmaceutical field, for example, preparation for oral administration such as tablet, capsule, troche, solution, suspension, etc., or injectable preparation such as injectable solution or suspension, ready-to-use injectable dry powder which can be reconstituted with distilled water for injection when it is injected, etc., by combining with a carrier conventionally used in the pharmaceutical field.

Suitable carrier which can be used in the composition of the present invention includes those conventionally used in the pharmaceutical field, for example, binder, lubricant, disintegrant, excipient, solubilizer, dispersing agent, stabilizing agent, suspending agent, coloring agent, perfume, etc. for oral preparation; and preservative, pain alleviating agent, solubilizing agent, stabilizing agent, etc. for injectable preparation. The pharmaceutical

preparation thus prepared can be administered orally or parenterally, for example, intravenously, subcutaneously or intraperitoneally. In addition, in order to prevent the active component from the decomposition with gastric acid, the oral preparation can be administered together with an antacid or in the enteric-coated form of the solid preparation such as tablet.

The dosage of the benzopyran derivative of formula (I) according to the present invention for human being can be suitably determined depending on absorption, inactivation and secretion of the active ingredient in the human body, age, sex and condition of subject patient, kinds and severity of disease to be treated. It is generally suitable to administer the compound of formula (I) in an amount of 1 to 500㎎, preferably 5 to 200㎎, per day for adult patient.

The present invention is more specifically explained by the following examples. However, it should be understood that the present invention is not limited to these examples in any manner.

Example 1

Synthesis of 7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran-4-one

7-Hydroxy-3-(4-hydroxyphenyl)-2,3-dihydro-4H-benzopyran-4-one (1.9g, 5.5 mmol) and methyl iodide (20.5㎖, 60 equ.) were added to dry tetrahydrofuran (20㎖) under argon atmosphere and the mixture was cooled to -78℃. 2.0M Lithium diisopropylamide (LDA) (4.2㎖) was slowly added dropwise thereto. Then the reaction mixture was slowly warmed to -20℃ with stirring and water was added thereto at the same temperature. The reaction solution was extracted with dichloromethane, dried over magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane: ethyl acetate = 8:1) to obtain 1.3g (yield: 66%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.87(d, 1H), 7.33(dd, 2H), 6.97(dd, 2H), 6.65(dd, 1H), 6.53(d, 1H), 5.16(s, 2H), 5.13(s, 2H), 4.81(d, 1H), 4.32(d, 1H), 3.45(s, 3H), 3.45(s, 3H), 1.45(s, 3H)

Example 2

Synthesis of (3RS,4RS)-4-[9-(t-butyldimethylsilyloxy)nonynyl]-4-hydoxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran

9-(t-Butyldimethylsilyloxy)-non-1-yne (0.46g, 1.8 mmol) was dissolved in dry tetrahydrofuran (8㎖) under argon atmosphere and then cooled to -78℃. 2.5M n-Butyllithium (n-BuLi) (0.7㎖, 1.68 mmol) was slowly added dropwise thereto and then the mixture was stirred for 30 minutes. To the mixture was added dropwise 7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran-4-one (200㎎, 6.6 mmol) dissolved in dry tetrahydrofuran (4㎖), and then the reaction mixture was slowly warmed to room temperature. The reaction solution was quenched with water and then extracted with ethyl acetate. The organic layer was separated, dried over magnesium sulfate and concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 350㎎ (yield: >100%) of the title compound as a colorless oil.

Example 3

Synthesis of (3RS,4RS)-4-(9-hydroxynonyl)-7-methoxymethyloxy-3-[4-(methoxy-methyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran

(3RS,4RS)-4-[9-(t-Butyldimethylsilyloxy)nonynyl]-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (340㎎, 0.56 mmol) was dissolved in ethyl acetate (10㎖) and then 10% Pd/C (180㎎) was added dropwise thereto. The reaction solution was stirred for 15 hours under hydrogen atmosphere, filtered and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1→1:1) to

obtain 90㎎ (yield: 33%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.05(d, 2H), 6.96(d, 2H), 6.88(d, 1H), 6.49(m, 2H), 5.10(s, 2H), 5.07(s, 2H), 4.45(d, 1H), 4.18(d, 1H), 3.53(t, 2H), 3.42(s, 6H), 2.55(m, 1H), 1.44(m, 2H), 1.23-0.99(brs, 17H)

Example 4

Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[9-(p-toluenesulfonyloxy)nonyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-4-(9-Hydroxynonyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (90㎎, 0.19 mmol) was dissolved in pyridine (2㎖) and dichloromethane (0.5㎖) and then cooled to 0℃. p-Toluenesulfonylchloride (0.12g, 0.63 mmol) was added dropwise thereto, and the mixture was stirred for 3 hours at room temperature, quenched with water and then extracted with ethyl acetate. The extracted organic substance was washed with 2N hydrochloric acid, dried over magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 105㎎ (yield: 88%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.71(dd, 2H), 7.25(d, 2H), 7.10(d, 2H), 6.95(d, 2H), 6.88(m, 1H), 6.49(m, 2H), 5.10(s, 2H), 5.06(s, 2H), 4.45(d, 1H), 4.18(d, 1H), 3.60(t, 2H), 3.41(s, 6H), 2.56(m, 1H), 2.35(s, 3H), 1.51(m, 2H), 1.17-0.99 (m, 17H)

Example 5

Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran

4,4,5,5,5-Pentafluoropentylthioacetate (0.21g, 0.9 mmol) was dissolved in

methanol (5㎖) and 2N aqueous sodium hydroxide solution (0.8㎖) was added thereto. The reaction solution was stirred for 30 minutes at room temperature and (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[9-(p-toluenesulfonyloxy)nonyl]-2,3-dihydro-4H-benzopyran (100㎎, 0.2 mmol) dissolved in methanol (2㎖) was added thereto. The reaction mixture was stirred for one hour at 60℃ and then cooled. After adding water, the reaction solution was extracted with ethyl acetate and the organic layer was dried over magnesium sulfate and concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 7:1) to obtain 100㎎ (yield: 97%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.16(d, 2H), 7.06(d, 2H), 6.98(d, 1H), 6.60(m, 2H), 5.21(s, 2H), 5.18(s, 2H), 4.55(d, 1H), 4.29(d, 1H), 3.52(s, 6H), 2.65(m, 1H), 2.60(t, 2H), 2.51(t, 2H), 2.15(m, 2H), 1.95(m, 2H), 1.57(m, 2H), 1.35-1.10(m, 17H)

Example 6

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-7-Methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran (100㎎, 0.15 mmol) and pyridinium p-toluenesulfonate (380㎎, 1.5 mmol) were dissolved in methanol (5㎖) and refluxed for 4 hours. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The extracted organic layer was dried over magnesium sulfate and concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 57㎎ (yield: 66%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.02(d, 2H), 6.83(d, 1H), 6.75(d, 2H), 6.29(m, 2H), 4.42(d, 1H), 4.14(d, 1H), 2.90(m, 1H), 2.53(t, 2H), 2.44(t, 2H),

2.20(m, 2H), 1.81(m, 2H), 1.48(m, 2H), 1.21-1.02(m, 17H)

Example 7

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran (47㎎, 0.08 mmol) was dissolved in 1,4-dioxane (1㎖), methanol (1㎖) and water (0.25㎖). $NaIO_4$ (20㎎, 0.093 mmol) was added dropwise thereto, and the reaction mixture was stirred for 12 hours at room temperature and then filtered. The filtrate was concentrated and the residue was subjected to column chromatography (n-hexane:ethyl acetate = 3:1→1:1) to obtain 35㎎ (yield: 73%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.05(d, 2H), 6.85(d, 1H), 6.80(d, 2H), 6.32(s, 2H), 5.20(s, 1H), 5.16(s, 1H), 4.48(d, 1H), 4.20(dd, 1H), 2.72(m, 2H), 2.56(m, 1H), 2.23(m, 4H), 1.76(m, 2H), 1.30(m, 2H), 1.21-0.90(m, 19H)

MS : 591(M+1)

Example 8

Synthesis of (3RS,4RS)-4-[8-(t-butyldimethylsilyloxy)octynyl]-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran

8-(t-Butyldimethylsilyloxy)oct-1-yne (0.6g, 2.5 mmol) was dissolved in dry tetrahydrofuran (8㎖) under argon atmosphere and then cooled to -78℃. 2.5M n-BuLi (0.94㎖, 2.35 mmol) was slowly added dropwise thereto and then the mixture was stirred for 30 minutes. To the mixture was added dropwise 7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran-4-one (300㎎, 0.84 mmol) dissolved in dry tetrahydrofuran (4㎖), and then the reaction mixture was slowly warmed to room temperature. After 3

hours, water was added to the reaction mixture. The reaction solution was extracted with ethyl acetate and the organic layer was dried over magnesium sulfate. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 500㎎ (yield: ~100%) of the title compound as a colorless oil.

Example 9

Synthesis of (3RS,4RS)-4-(8-hydroxyoctyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran

(3RS,4RS)-4-[8-(t-Butyldimethylsilyloxy)octynyl]-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (500㎎, 0.84 mmol) was dissolved in ethyl acetate (14㎖) and then 10% Pd/C (230㎎) was added thereto. The reaction mixture was stirred under hydrogen atmosphere. After 5 hours, the reaction solution was filtered and then concentrated. The residue was subjected to column chromatography (n-hexane: ethyl acetate = 4:1→1:1) to obtain 80㎎ (yield: 33%) of the title compound as a colorless oil.

Example 10

Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[8-(p-toluenesulfonyloxy)octyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-4-(8-Hydroxyoctyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (80㎎, 0.17 mmol) was dissolved in pyridine (2㎖) and dichloromethane (0.5㎖) and then cooled to 0℃. p-Toluenesulfonylchloride (0.12g, 0.63 mmol) was added thereto and the mixture was stirred for 6 hours at room temperature. Water was added thereto at 0℃ and the reaction solution was extracted with ethyl acetate, washed with saturated saline and then dried over magnesium sulfate. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 110㎎ (yield: ~100%) of the title compound as a colorless oil.

Example 11

Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylthio)octyl]-2,3-dihydro-4H-benzopyran

4,4,5,5,5-Pentafluoropentylthioacetate (0.28g, 1.2 mmol) was dissolved in methanol (5㎖) and 2N aqueous sodium hydroxide solution (1㎖) was added thereto. The reaction solution was stirred for 40 minutes at room temperature and (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[8-(p-toluenesulfonyloxy)octyl]-2,3-dihydro-4H-benzopyran (100㎎, 0.2 mmol) dissolved in methanol (2㎖) was added thereto. The reaction mixture was stirred for 2 hours at 60℃ and then cooled. After adding water, the reaction solution was extracted with ethyl acetate and the organic layer was dried over magnesium sulfate and concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 8:1) to obtain 120㎎ (yield: ~100%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.16(d, 2H), 7.10(d, 2H), 6.97(d, 1H), 6.60(m, 2H), 5.21(s, 2H), 5.18(s, 2H), 4.55(d, 1H), 4.30(d, 1H), 3.52(s, 6H), 2.65(m, 1H), 2.60(t, 2H), 2.52(t, 2H), 2.20(m, 2H), 1.91(m, 2H), 1.53(m, 2H), 1.32-1.10 (m, 15H)

Example 12

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylthio)octyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-7-Methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylthio)octyl]-2,3-dihydro-4H-benzopyran (120㎎, 0.19 mmol) and pyridinium p-toluenesulfonate (580㎎, 2.3 mmol) were dissolved in methanol (8㎖) and then refluxed for 7 hours. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer was separated, washed with water, dried over magnesium sulfate and then concentrated. The residue was subjected to

column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 64㎎ (yield: 69%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.01(dd, 2H), 6.83(d, 1H), 6.77(d, 2H), 6.30(d, 2H), 4.96(s, 1H), 4.76(s, 1H), 4.44(d, 2H), 4.18(d, 2H), 2.51(m, 3H), 2.40(t, 2H), 2.05(m, 2H), 1.81(m, 2H), 1.44(m, 2H), 1.21-0.98(m, 15H)

MS : 561(M+1)

Example 13

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfinyl)octyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylthio)octyl]-2,3-dihydro-4H-benzopyran (53㎎, 0.095 mmol) was dissolved in 1,4- dioxane (1.2㎖), methanol (1.2㎖) and water (0.3㎖). $NaIO_4$ (24㎎, 0.11 mmol) was added dropwise thereto, and the reaction mixture was stirred for 8 hours at room temperature and then filtered. The filtrate was concentrated and the residue was subjected to column chromatography (n-hexane:ethyl acetate = 2:1) to obtain 38㎎ (yield: 70%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 6.98(dd, 2H), 6.83(m, 3H), 6.33(d, 2H), 4.16(d, 1H), 2.72(m, 3H), 2.48(m, 2H), 2.16-2.11(m, 4H), 1.62(m, 2H), 1.24-0.93(m, 15H)

MS : 577(M+1)

Example 14

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfonyl)nonyl]-2,3-dihydro-4H-benzopyran

(3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran (65㎎, 0.113 mmol) was

dissolved in methanol (3mℓ) and water (1.5mℓ). Oxone (210mg, 0.34 mmol) was added dropwise thereto, and the reaction mixture was stirred for 14 hours at room temperature. After adding water, the reaction solution was extracted with ethyl acetate, dried over magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1 →2:1) to obtain 28mg (yield: 41%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.01(d, 2H), 6.83(d, 1H), 6.77(d, 2H), 6.32(s, 2H), 5.45(s, 1H), 4.95(s, 1H), 4.43(d, 1H), 4.17(d, 1H), 2.99(t, 2H), 2.90(t, 2H), 2.50(m, 1H), 2.19-2.12(m, 4H), 1.30(m, 2H), 1.28-0.99(m, 17H)

MS : 607(M+1)

Example 15

Synthesis of 4-(4-hydroxyphenyl)-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran

Under nitrogen atmosphere, 3-bromomagnesium phenyl trimethylsilyl ether prepared from 3-bromophenyl trimethylsilyl ether (2.35g, 9.57 mmol) and magnesium turning (0.23g, 9.57 mmol) in dry tetrahydrofuran (3mℓ) was cooled to -78℃. 7-Methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran-4-one (1g, 2.9 mmol) dissolved in dry tetrahydrofuran (2mℓ) was slowly added dropwise thereto, and the mixture was stirred for one hour. The reaction solution was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the organic solvent. The concentrate was then subjected to column chromatography (n-hexane:ethyl acteate = 4:1) to obtain 903mg (yield: 74%) of the title compound as a foam.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.05(dd, 1H), 6.98(d, 2H), 6.81(d, 2H), 6.73(s, 1H), 6.67(t, 2H), 6.55(d, 3H), 5.21(s, 2H), 5.12(s, 2H), 4.71(dd, 1H), 4.21(d, 1H), 3.50(dd, 1H), 3.42(s, 6H)

Example 16

Synthesis of 4-[4-(5-chloropentyloxy)phenyl]-4-hydoxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran

4-(4-Hydroxyphenyl)-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran (180㎎, 0.4 mmol), 1-bromo-5-chloropentane (0.39㎖, 2 mmol) and 2N aqueous sodium hydroxide solution (70㎕, 2 mmol) were dissolved in acetone (4㎖) and then refluxed for 6 hours. The reaction mixture was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The concentrate was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 247㎎ (yield: 97%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.10(m, 1H), 6.78(m, 5H), 6.70(dd, 3H), 6.63(s, 1H), 6.45(dd, 1H), 5.23(s, 2H), 5.14(s, 2H), 4.65(t, 1H), 4.22(dd, 1H), 3.83(m, 2H), 3.72(t, 2H), 3.43(s, 6H), 1.82(m, 2H), 1.48(m, 2H), 1.17(t, 2H)

Example 17

Synthesis of 4-hydroxy-4-[4-(5-iodopentyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran

4-[4-(5-Chloropentyloxy)phenyl]-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran (167㎎, 0.3 mmol) and sodium iodide (139㎎, 0.9 mmol) were dissolved in methyl ethyl ketone (5㎖) and then refluxed for 12 hours. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The concentrate was subjected to column chromatography (n-hexane:ethyl acetate =

4:1) to obtain 142㎎ (yield: 75%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.05(m, 1H), 6.72(m, 5H), 6.65(dd, 3H), 6.55(s, 1H), 6.41(dd, 1H), 5.16(s, 2H), 5.13(s, 2H), 4.61(t, 1H), 4.21(dd, 1H), 3.81(m, 2H), 3.41(s, 6H), 3.13(t, 2H), 1.72(m, 2H), 1.56-1.45(m, 2H), 1.16(t, 2H)

Example 18

Synthesis of 4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-4-[4-(5-(4,4,5,5,5-pentafluoropentylthio)pentyloxy)phenyl]-2,3-dihydro-4H-benzo-pyran

4,4,5,5,5-Pentafluoropentylthioacetate (254㎎, 1.1 mmol) was dissolved in methanol (3㎖) and 2N aqueous sodium hydroxide solution (0.43㎖) was added thereto. The reaction solution was stirred for one hour at room temperature and 4-hydroxy-4-[4-(5-iodopentyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran (142㎎, 0.22 mmol) dissolved in methanol (2㎖) was added dropwise thereto. The reaction mixture was stirred for 2 hours at 60℃ and then cooled to room temperature. After adding water, the reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The concentrate was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 153㎎ (yield: 98%) of the title compound as a colorless oil.

^{1}H-NMR($CDCl_3$, $CDCl_3$) : δ 7.20(t, 1H), 6.92(m, 5H), 6.78(dd, 3H), 6.63(d, 1H), 6.56(dd, 1H), 5.25(s, 2H), 5.20(s, 2H), 4.72(t, 1H), 4.20(dd, 1H), 3.80(m, 2H), 3.42(s, 6H), 2.61(m, 4H), 2.10(m, 2H), 1.72(m, 2H), 1.55(m, 4H), 1.25(s, 2H)

Example 19

Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-4-[4-(5-(4,4,5,5,5-pentafluoropentyl

-thio)pentyloxy)phenyl]-2H-benzopyran

4-Hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-4-[4-(5-(4,4,5,5,5-pentafluoropentylthio)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran (220 ㎎, 0.3 mmol) and pyridinium p-toluenesulfonate (789㎎, 3 mmol) were dissolved in methanol (8㎖) and then refluxed for 8 hours. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The concentrate was subjected to column chromatography (n-hexane:ethyl acetate = 1:1) to obtain 142㎎ (yield: 78%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.12(q, 1H), 6.80(dd, 2H), 6.72(d, 1H), 6.65(dd, 2H), 6.52(dd, 3H), 6.35(d, 1H), 6.20(dd, 1H), 5.06(s, 2H), 3.76(t, 2H), 2.63(m, 4H), 2.22-2.01(m, 2H), 1.83(m, 2H), 1.75-1.62(m, 2H), 1.45-1.37(m, 2H), 1.20(m, 2H), 0.91-0.80(t, 2H)

Example 20

Synthesis of 4-methoxyphenylglyoxylic ethyl ester



Aluminum chloride (84.30g, 632 mmol) was added to chloroform (300 ㎖) and chloroglyoxylic ethyl ester (60g, 439 mmol) was added dropwise to the resulting suspension over 20 minutes at 0℃. The reaction mixture was stirred for 40 minutes at 5℃. At the same temperature, anisole (68.79g, 636 mmol) was slowly added dropwise to the reaction solution and then stirred for 12 hours at 10℃. When the reaction is completed, the reaction solution was

cooled and, after adding cooling water (100mℓ), extracted with dichloromethane. The extract was dried over anhydrous magnesium sulfate and then concentrated to obtain the title compound as a yellow solid (TLC identification). The resulting compound was used in the next reaction without further purification.

Example 21

Synthesis of 4-methoxyphenylglyoxylic acid



4-Methoxyphenylglyoxylic ethyl ester obtained in Example 20 was dissolved in 20% sodium hydroxide (60mℓ) and methanol (600mℓ) and then stirred for 3 hours with heating at 80℃. When the reaction is completed, the reaction solution was extracted with diethyl ether (200mℓ) and the obtained aqueous solution was acidified (pH 1-2) with hydrochloric acid. The resulting aqueous acidic solution was extracted with dichloromethane, and the extract was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure to remove the organic solvent to obtain 34.63g (yield in two reaction steps: 43%) of the title compound as a pale violet solid.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 8.59(brs, 1H, COOH), 8.44(d, ^{3}J=8.9Hz, 2H, Ar-H), 6.99(d, ^{3}J=8.9Hz, 2H, Ar-H), 3.92(s, 3H, OCH_3)

Example 22

Synthesis of 2-hydroxy-2-(4-methoxyphenyl)propionic acid



Methyl iodide (55㎖, 880 mmol) was slowly added to a solution of magnesium (23g) in diethyl ether (500㎖) at -20℃ and then stirred for 3 hours at room temperature. To the resulting suspension was slowly added dropwise 4-methoxyphenylglyoxylic acid (34.6g, 192 mmol), as prepared in Example 21, dissolved in dry tetrahydrofuran (100㎖) at 0℃, and the reaction mixture was stirred for about 12 hours at room temperature. After adding cooling water, the reaction solution was extracted with ethyl acetate and the organic layer was washed with water and saturated sodium thiosulfate solution and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure to remove the organic solvent to obtain 35g (yield: 93%) of the title compound as a yellow solid.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.39(d, ^{3}J=8.9Hz, 2H, Ar-H), 7.16(s, 1H, COOH), 6.89(d, ^{3}J=8.5Hz, 2H, Ar-H), 4.90(brs, 1H, OH), 3.80(s, 3H, OCH_3), 1.71(s, 3H, CH_3)

Example 23

Synthesis of 2-(4-methoxyphenyl)acrylic acid



2-Hydroxy-2-(4-methoxyphenyl)propionic acid (35g, 178 mmol) was dissolved in dioxane (700㎖) and concentrated sulfuric acid (60㎖) was added

thereto. The reaction mixture was refluxed for 2 hours under heating. The reaction solution was cooled and, after adding water, extracted with ethyl acetate. The organic layer was washed with saturated sodium thiosulfate solution and water, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure to obtain 24.8g (yield: 72%) of the title compound as a brown solid.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.39(d, ^{3}J=8.5Hz, 2H, Ar-H), 7:40(s, 1H, COOH), 6.89(d, ^{3}J=8.5Hz, 2H, Ar-H), 6.45(s, 1H, $=CH_2$), 5.96(s, 1H, $=CH_2$), 3.82(s, 3H, OCH_3)

Example 24

Synthesis of 2-(4-methoxyphenyl)-3-(3-methoxyphenylthio)propionic acid



3-Methoxybenzenethiol(2.5mℓ, 20.1 mmol) was added to 2-(4-methoxyphenyl)acrylic acid (3g, 16.8 mmol) and stirred for 21 hours with heating at 125℃. The reaction solution was extracted with diethyl ether, and the ether solution was washed with 0.1N iodine-potassium iodide solution, water and saturated sodium chloride solution and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure to remove the organic solvent to obtain the title compound as a brown oil. The resulting compound was used in the next reaction without further purification.

Example 25

Synthesis of 7-methoxy-3-(4-methoxyphenyl)thiochroman-4-one



2-(4-Methoxyphenyl)-3-(3-methoxyphenylthio)propionic acid obtained in Example 24 was dissolved in benzene (20㎖) and thionyl chloride (4.1㎖, 55.9 mmol) was added thereto. The reaction mixture was heated for 2 hours at 80℃. When the reaction is completed, the reaction solution was concentrated under reduced pressure to remove benzene and cooled to 5℃. Benzene (10 ㎖) was added to the reaction solution and then tin(IV) chloride (4.1㎖, 34.9 mmol) was slowly added dropwise thereto. The reaction mixture was stirred for 12 hours and then water (30㎖), concentrated hydrochloric acid (10㎖) and chloroform (30㎖) were added thereto. The reaction solution was heated under refluxing for one hour and extracted with chloroform. The organic layer was washed with water and sodium hydrogen carbonate solution, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate = 8:2) to obtain 1g (yield in two reaction steps: 20%) of the title compound as a yellow solid.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 8.13(d, ^{3}J=9.5Hz, 1H, C5-H), 7.12(d, ^{3}J=8.9Hz, 2H, Ar-H), 6.88(d, ^{3}J=8.6Hz, 2H, Ar-H), 6.73(m, 2H, Ar-H), 4.01(dd, ^{3}J=10.5 and 3.9Hz, 1H, C3-H), 3.85(s, 3H, OCH_3), 3.79(s, 3H, OCH_3), 3.53(dd, ^{3}J=10.5 and 13.2Hz, 1H, C2-H), 3.31(dd, ^{3}J=13.2 and 3.9Hz, 1H, C2-H)

Example 26

Synthesis of 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one



To 7-methoxy--3-(4-methoxyphenyl)thiochroman-4-one (725㎎, 2.41 mmol) obtained in Example 25 was added dry tetrahydrofuran (30㎖). Then lithium diisopropylamide (2.41㎖, 4.83 mmol, 2.0 mol hexane/tetrahydrofuran solution) was added dropwise thereto at -78℃. The reaction mixture was stirred for 45 minutes and methyl iodide (7.5㎖, 120.6 mmol) was added thereto. The reaction solution was stirred for one hour at -78℃ and for 24 hours at -10℃ and, after adding water, extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane: ethyl acetate = 9:1) to obtain 550㎎ (yield: 72%) of the title compound as a yellow solid.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 8.17(d, ^{3}J=8.9Hz, 1H, C5-H), 7.14(dd, ^{3}J=8.9Hz, ^{4}J=2.0Hz, 2H, Ar-H), 6.82(dd, ^{3}J=8.9Hz, 2.0Hz, 2H, Ar-H), 6.70(dd, ^{3}J=8.9Hz, ^{4}J=2.3Hz, 1H, C6-H), 6.57(d, ^{4}J=2.7Hz, 1H, C8-H), 3.78(s, 3H, OCH_3), 3.75(s, 3H, OCH_3), 3.44(d, ^{2}J=4.9Hz, 2H, 2×C2-H), 1.58(s, 3H, C3-CH_3)

Example 27

Synthesis of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-4-hydroxy-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman



To 9-(t-butyldimethylsilyloxy)-1-nonyne (2.23g, 8.75 mmol) was added dry tetrahydrofuran (30mℓ). Then n-butyl lithium (4.65mℓ, 7.87 mol, 1.69 mol/ℓ tetrahydrofuran solution) was added dropwise thereto at -78℃ and the resulting mixture was stirred for one hour at -20℃. At the same temperature, to the reaction solution was added 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one (550mg, 1.75 mmol), as obtained in Example 26, dissolved in tetrahydrofuran (20mℓ), and then the mixture was stirred for 24 hours at -10℃. When the reaction is completed, saturated ammonium chloride solution was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate = 9:1) to obtain 946mg (yield: 95%) of the title compound as a white solid.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.86(d, ^{3}J=8.5Hz, 1H, Ar-H), 7.59(d, ^{3}J=8.9Hz, 2H, Ar-H), 6.87(d, ^{3}J=8.9Hz, 2H, Ar-H), 6.63(m, 2H, Ar-H), 4.25(d, ^{2}J=12.6Hz, 1H, C2-H), 3.81(s, 3H, OCH_3), 3.77(s, 3H, OCH_3), 3.59(t, ^{3}J=6.6Hz, 2H, CH_2-OTBS), 2.70(d, ^{2}J=12.6Hz, 1H, C2-H), 2.18(t, ^{2}J=6.6Hz, 3H, CH_2-C≡C and OH), 1.48(s, 3H, C3-CH_3), 1.36(m, 10H, alkyl-H), 0.89(s, 9H, t-butyl-H), 0.04(s, 6H, 2×CH_3)

Example 28

Synthesis of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman



Dichloromethane (30mℓ) was added to 4-[9-(t-butyldimethylsilyloxy)-1-

nonynyl]-4-hydroxy-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (946㎎, 1.66 mmol) obtained in Example 27, and then zinc iodide (795㎎, 2.49 mmol) and sodium cyanoborohydride (782㎎, 12.45 mmol) were added thereto. The reaction solution was stirred for 24 hours at room temperature and, after adding water, extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate = 9:1) to obtain 569㎎ (yield: 62%, 3RS,4RS/3RS,4SR=5:1) of the title compound as a white solid.

^{1}H-NMR(270MHz, $CDCl_3$, 3RS,4RS-compound) : δ 7.25(m, 3H, Ar-H), 6.82(d, ^{3}J=8.9Hz, 2H, Ar-H), 6.68(m, 2H, Ar-H), 3.78(s, 3H, OCH_3), 3.76(s, 3H, OCH_3), 3.72(s, 1H, C4-H), 3.76(d, ^{2}J=12.2Hz, 1H, C2-H), 3.58(t, ^{3}J=6.6Hz, 2H, CH_2-OTBS), 2.99(d, ^{2}J=12.2Hz, 1H, C2-H), 2.02(m, 2H, CH_2-C≡C), 1.44(s, 3H, C3-CH_3), 1.20(m, 10H, alkyl-H), 0.89(s, 9H, t-butyl-H), 0.05(s, 6H, 2×CH_3)

Example 29

Synthesis of 4-[9-(t-butyldimethylsilyloxy)nonyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman



Methanol (60㎖) and 10% Pd/C (500㎎) were added to 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (560㎎, 1.01 mmol) obtained in Example 28, and the mixture was stirred for 2 days under hydrogen gas (normal pressure). Ethyl acetate was added to the reaction solution which was then filtered, washed several times with ethyl

acetate and concentrated under reduced pressure to remove the organic solvent. To the residue were added methanol (60㎖) and 10% Pd/C (300㎎), and the reaction mixture was stirred for 8 hours at 5 atomsphere under hydrogen gas. Ethyl acetate was added again to the reaction solution which was then filtered and concentrated under reduced pressure to obtain 450㎎ (yield: 80%) of the title compound as an oil. The resulting compound was used in the next reaction without further purification.

^{1}H-NMR(270MHz, $CDCl_3$, 3RS,4RS-compound) : δ 7.28(d, ^{3}J=8.9Hz, 2H, Ar-H), 6.91(m, 3H, Ar-H), 6.72(d, ^{4}J=2.3Hz, 1H, C8-H), 6.58(dd, ^{3}J=8.6Hz, ^{4}J=2.6Hz, 1H, Ar-H), 3.82(s, 3H, OCH_3), 3.78(s, 3H, OCH_3), 3.64(d, ^{2}J=11.5Hz, 1H, C2-H), 3.56(t, ^{3}J=6.6Hz, 2H, CH_2-OTBS), 2.98(d, ^{2}J=11.5Hz, 1H, C2-H), 2.71(brt, 1H, C4-H), 1.48-1.17(m, 19H, C3-CH_3 and alkyl-H), 0.88(s, 9H, t-butyl-H), 0.03(s, 6H, $2\times CH_3$)

Example 30

Synthesis of 4-(9-hydroxynonyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman



4-[9-(t-Butyldimethylsilyloxy)nonyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (400㎎, 0.72 mmol) obtained in Example 29 was dissolved in tetrahydrofuran (40㎖), and 3N-HCl (2㎖) was added thereto. The reaction mixture was stirred for 3 hours at room temperature. When the reaction is completed, water was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with

column chromatography (n-hexane:ethyl acetate = 7:3) to obtain 235mg (yield: 74%, 3RS,4RS/3RS,4SR=9:1) of the title compound as a white solid.

^{1}H-NMR(270MHz, $CDCl_3$, 3RS,4RS-compound) : δ 7.29(d, ^{3}J=8.9Hz, 2H, Ar-H), 6.91(m, 3H, Ar-H), 6.71(m, 1H, Ar-H), 6.58(m, 1H, Ar-H), 3.82(s, 3H, OCH_3), 3.78(s, 3H, OCH_3), 3.68(m, 4H, CH_2-OH, C2-H), 2.98(d, ^{2}J=11.6Hz, 1H, C2-H), 2.78(brt, 1H, C4-H), 1.56-1.08(m, 19H, C3-CH_3 and alkyl-H)

Example 31

Synthesis of 4-(9-methanesulfonyloxynonyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman



4-(9-Hydroxynonyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (131mg, 0.30 mmol) obtained in Example 30 was dissolved in dichloromethane (12mℓ) and then triethylamine (0.2mℓ, 1.48 mmol) and methanesulfonyl chloride (0.11mℓ, 1.48 mmol) were added thereto. The reaction mixture was stirred for 40 minutes at room temperature. When the reaction is completed, water was added to the reaction solution which was then extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution and dried over anhydrous magnesium sulfate. The residue was purified with column chromatography (n-hexane:ethyl acetate = 7:3) to obtain 141mg (yield: 91%, 3RS,4RS/3RS,4SR= 8.5/1) of the title compound as an oil.

^{1}H-NMR(270MHz, $CDCl_3$, 3RS,4RS-compound) : δ 7.29(d, ^{3}J=8.9Hz, 2H, Ar-H), 6.91(m, 3H, Ar-H), 6.70(d, ^{4}J=2.3Hz, 1H, C8-H), 6.58(dd,

^{3}J=8.5Hz, ^{4}J=2.3Hz, 1H, Ar-H), 4.18(t, ^{3}J=6.6Hz, 2H, OCH_2), 3.82(s, 3H, OCH_3), 3.78(s, 3H, OCH_3), 3.64(d, ^{2}J=11.3Hz, 1H, C2-H), 2.99(s, 3H, OSO_2CH_3), 2.97(brd, ^{2}J=not resolved, 1H, C2-H), 2.78(brt, 1H, C4+1), 1.63(m, 3H, alkyl-H), 1.37-1.08(m, 16H, C3-CH_3 and alkyl-H)

Example 32

Synthesis of 7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-thiochroman



4,4,5,5,5-Pentafluoropentylthioacetate (424㎎, 1.89 mmol) was dissolved in absolute methanol (10㎖) and 1M sodium methoxide (1.62㎖) was added thereto. The reaction solution was stirred for one hour at room temperature and 4-(9-methanesulfonyloxynonyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (141㎎, 0.27 mmol), as obtained in Example 31, dissolved in dry tetrahydrofuran (10㎖) was added dropwise thereto at room temperature. The reaction mixture was stirred for 24 hours. When the reaction is completed, water was added to the reaction solution which was then extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure to remove the organic solvent and then purified with column chromatography (n-hexane:ethyl acetate = 9:1) to obtain 164㎎ (yield: 98%, 3RS,4RS/3RS,4SR=8.5/1) of the title compound as a yellow oil.

^{1}H-NMR(270MHz, $CDCl_3$, 3RS,4RS-compound) : δ 7.29(d, ^{3}J=8.9Hz, 2H, Ar-H), 6.90(m, 3H, Ar-H), 6.72(d, ^{4}J=2.7Hz, 1H, C8-H), 6.58(dd,

^{3}J=8.6Hz, ^{4}J=2.7Hz, 1H, Ar-H), 3.83(d, ^{2}J=11.9Hz, 1H, C2-H), 3.82(s, 3H, OCH_3), 3.78(s, 3H, OCH_3), 2.98(d, ^{2}J=11.9Hz, 1H, C2-H), 2.74(brt, 1H, C4-H), 2.57(t, ^{3}J=6.9Hz, 2H, S-CH_2), 2.47(t, ^{3}J=6.9Hz, 2H, S-CH_2), 2.13(m, 2H, alkyl-H), 1.88(m, 2H, alkyl-H), 1.50-1.08(m, 19H, C3-CH_3 and alkyl-H)

Example 33

Synthesis of (3RS,4RS)- and (3RS,4SR)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman



7-Methoxy-3-(4-methoxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentyl-thio)nonyl]-thiochroman (164㎎, 0.26 mmol) obtained in Example 32 was dissolved in dichloromethane (18㎖) and boron tribromide (1.85㎖, 1.0 mol/ℓ dichloromethane solution) was added thereto at -78℃. The reaction mixture was stirred for one hour at the same temperature and for about 10 hours at room temperature. When the reaction is completed, water was added to the reaction solution which was then extracted with ethyl acetate. The organic layer was washed with sodium hydrogen sulfite solution and water and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure to remove the organic solvent and then purified with column chromatography (n-hexane:ethyl acetate = 8:2) to obtain 109㎎ (yield: 70%) of the title 3RS,4RS-compound and 9㎎ (yield: 6%) of the 3RS,4SR-compound as a white solid.

^{1}H-NMR(270MHz, $CDCl_3$, 3RS,4RS-compound) : δ 7.25(d, ^{3}J=8.6Hz, 2H, Ar-H), 6.85(dd, ^{3}J=8.6 and 8.2Hz, 3H, Ar-H), 6.67(d, ^{4}J=2.6Hz, 1H, C8-H), 6.50(dd, ^{3}J=8.3Hz, ^{4}J=2.3Hz, 1H, Ar-H), 4.94(brs, 1H, OH), 4.75(brs,

1H, OH), 3.62(d, ^{2}J=11.6Hz, 1H, C2-H), 2.96(d, ^{2}J=11.6Hz, 1H, C2-H), 2.69(brt, 1H, C4-H), 2.58(t, ^{3}J=6.9Hz, 2H, S-CH_2), 2.48(t, ^{3}J=6.9Hz, 2H, S-CH_2), 2.12(m, 2H, alkyl-H), 1.88(m, 2H, alkyl-H), 1.69-1.07(m, 19H, C3-CH_3 and alkyl-H)

^{1}H-NMR(270MHz, $CDCl_3$, 3RS,4SR-compound) : δ 7.24(d, ^{3}J=8.6Hz, 2H, Ar-H), 6.65(m, 3H, Ar-H), 6.48(d, ^{4}J=2.4Hz, 1H, Ar-H), 6.31(dd, ^{3}J=8.3Hz, ^{4}J=2.3Hz, 1H, Ar-H), 4.54(brs, 1H, OH), 4.46(brs, 1H, OH), 3.21(2×d, ^{2}J=not resolved, 2H, 2×C2-H), 2.85(brt, 1H, C4-H), 2.58(t, ^{3}J=6.9Hz, 2H, S-CH_2), 2.50(t, ^{3}J=6.9Hz, 2H, S-CH_2), 2.16(m, 2H, alkyl-H), 1.87(m, 2H, alkyl-H), 1.63-1.16(m, 19H, C3-CH_3 and alkyl-H)

Example 34

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman



Methanol (16mℓ) and water (4mℓ) were added to the mixture of (3RS, 4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio) -nonyl]thiochroman (85mg, 0.14 mmol) obtained in Example 33 and $NaIO_4$ (34 mg, 0.16 mmol), and the reaction mixture was stirred for 3.5 hours at room temperature. Water was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and then purified with preparative TLC (n-hexane:ethyl acetate = 1:1) to obtain 39mg (yield: 45%) of the title compound as a white solid. In this reaction, 13mg (15%) of the unreacted starting 3RS,4RS-compound was recovered.

^{1}H-NMR(270MHz, CD_3OD) : δ 7.21(d, ^{3}J=8.6Hz, 2H, Ar-H), 6.81(d, ^{3}J=8.3Hz, 1H, C5-H), 6.73(d, ^{3}J=8.6Hz, 2H, Ar-H), 6.51(d, ^{4}J=2.3Hz, 1H, C8-H), 6.39(dd, ^{3}J=8.3Hz, ^{4}J=2.3Hz, 1H, C6-H), 3.57(d, ^{2}J=11.5Hz, 1H, C2-H), 3.26(d, ^{2}J=11.5Hz, 1H, C2-H), 2.80(m, 4H, 2×S(O)-CH_2), 2.27(m, 2H, alkyl-H), 2.04(m, 2H, alkyl-H), 1.67(m, 2H, alkyl-H), 1.54-1.02(m, 17H, C3-CH_3 and alkyl-H)

Example 35

Synthesis of (3RS,4RS)-4-hydroxy-4-(3-hydroxyphenyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran



Under argon atmosphere 3-bromomagnesium phenyl trimethylsilyl ether was prepared from 3-bromophenyl trimethylsilyl ether (3g, 12.24 mmol) and magnesium turning (300㎎, 12.34 mmol) in dry tetrahydrofuran (10㎖) and cooled to 0℃. 7-Methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran-4-one (900㎎, 2.51 mmol) dissolved in dry tetrahydrofuran (5㎖) was slowly added dropwise thereto and then refluxed for 12 hours. The reaction mixture was cooled to room temperature, quenched with water and then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 2:1) to obtain 760㎎ (yield: 67%) of the title compound as a foam.

Example 36

Synthesis of (3RS,4RS)-4-(3-hydroxyphenyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran



(3RS,4RS)-4-Hydroxy-4-(3-hydroxyphenyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (1.19g, 2.63 mmol) prepared in Example 35 was dissolved in methanol (50mℓ), and 10% Pd/C (200 mg) was slowly added dropwise thereto. The reaction mixture was stirred under hydrogen atmosphere for 12 hours and then filtered. The filtrate was concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 8:1) to obtain 594mg (yield: 50%) of the title compound as a colorless foam.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.17(s, 1H), 6.81(d, 2H), 6.76(s, 1H), 6.71(d, 2H), 6.59(s, 1H), 6.47(d, 1H), 6.41(m, 1H), 6.08(d, 1H), 5.92(s, 1H), 5.30(s, 1H), 5.08(s, 2H), 5.05(s, 2H), 4.53(d, 1H), 3.94(d, 1H), 3.81(s, 1H), 3.39(s, 3H), 3.36(s, 3H), 1.42(s, 3H)

Example 37

Synthesis of (3RS,4RS)-4-[3-(4-chlorobutyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran



(3RS,4RS)-4-(3-Hydroxyphenyl)-7-methoxymethyloxy-3-[4-(methoxymethyl-oxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (260㎎, 0.59 mmol), 1-bromo-4-chlorobutane (0.8㎖, 2.98 mmol) and aqueous 2N-NaOH solution (0.8㎖) were dissolved in acetone (10㎖) and then stirred for 4 hours at 50℃. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 300㎎ (yield: 96%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.17(d, 1H), 6.79(d, 2H), 6.70(d, 2H), 6.69(s, 1H), 6.59(s, 1H), 6.45(m, 2H), 6.15(d, 1H), 5.98(s, 1H), 5.06(s, 2H), 5.01(s, 2H), 4.53(d, 1H), 3.96(d, 1H), 3.84(s, 1H), 3.60-3.47(m, 4H), 3.41(s, 3H), 3.35(s, 3H), 1.9-1.7(m, 4H), 1.42(s, 3H)

Example 38

Synthesis of (3RS,4RS)-4-[3-(4-iodobutyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran



(3RS,4RS)-4-[3-(4-Chlorobutyloxy)phenyl]-7-methoxymethyloxy-3-[4-(meth-oxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (300㎎, 0.57 ㎜ol) and sodium iodide (260㎎, 1.73 mmol) were dissolved in methyl ethyl ketone (30㎖) and then refluxed for 12 hours. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution

was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 340㎎ (yield: 97%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.17(d, 1H), 6.79(d, 2H), 6.70(d, 2H), 6.69(s, 1H), 6.59(s, 1H), 6.45(m, 2H), 6.15(d, 1H), 5.98(s, 1H), 5.06(s, 2H), 5.01(s, 2H), 4.53(d, 1H), 3.96(d, 1H), 3.84(s, 1H), 3.60-3.45(m, 2H), 3.41(s, 3H), 3.35(s, 3H), 3.13(t, 2H), 1.9-1.7(m, 4H), 1.42(s, 3H)

Example 39

Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran



4,4,5,5,5-Pentafluoropentylthioacetate (650㎎, 2.75 mmol) was dissolved in methanol (2㎖) and aqueous 2N-NaOH solution (1.4㎖) was added thereto. The mixture was stirred for one hour at room temperature. (3RS,4RS)-4-[3-(4-Iodobutyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-2,3-dihydro-4H-benzopyran (340㎎, 0.55 mmol) dissolved in methanol (10㎖) was added dropwise thereto and then stirred for 12 hours at 60℃. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and

concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 346mg (yield: 92%) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.18(d, 1H), 6.80(d, 2H), 6.71(d, 2H), 6.70(s, 1H), 6.60(s, 1H), 6.46(m, 2H), 6.16(d, 1H), 6.00(s, 1H), 5.07(s, 2H), 5.02(s, 2H), 4.54(d, 1H), 3.97(d, 1H), 3.85(s, 1H), 3.60-3.45(m, 2H), 3.42(s, 3H), 3.36(s, 3H), 2.5(m, 4H), 2.1(m, 2H), 1.81(m, 2H), 1.67(m, 4H), 1.43(s, 3H)

Example 40

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran



(3RS,4RS)-7-Methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran (274mg, 0.4 mmol) and pyridinium p-toluenesulfonate (508mg, 2.02 mmol) were dissolved in methanol (10mℓ) and then refluxed for 14 hours. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was washed with water, dried over anhydrous magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 167mg (yield: 75%) of the title compound as a white foam.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 6.83(m, 1H), 6.74(d, 2H), 6.65(d, 1H), 6.53(d, 2H), 6.5(m, 1H), 6.39(s, 1H), 6.27(m, 1H), 6.19(d, 1H), 5.96(s, 1H), 5.29(s, 1H), 5.22(s, 1H), 4.52(d, 1H), 3.95(d, 1H), 3.81(s, 1H), 3.6(m, 2H), 2.49(m, 4H), 2.1(m, 2H), 1.82(m, 2H), 1.65(m, 4H), 1.42(s, 3H)

Example 41

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylsulfinyl)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran



(3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran (72㎎, 0.12 mmol) was dissolved in methanol (5㎖) and water (1㎖), and $NaIO_4$ (35㎎, 0.16 mmol) was added thereto. The reaction solution was stirred for 12 hours at room temperature and then extracted with ethyl acetate. The organic layer thus separated was washed with water, dried over anhydrous magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 2:1) to obtain 66㎎ (yield: 89%) of the title compound as a white foam.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 6.91(t, 1H), 6.72(s, 1H), 6.67(s, 1H), 6.58(d, 2H), 6.47(d, 1H), 6.41(s, 1H), 6.28(d, 2H), 6.17(s, 1H), 5.78(d, 1H), 4.45(m, 1H), 4.06(m, 1H), 3.78(s, 1H), 3.6(m, 1H), 3.45(m, 1H), 2.7(m, 4H), 2.2(m, 4H), 1.7(m, 4H), 1.42(s, 3H)

Example 42

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylsulfonyl)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran



(3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran (95㎎, 0.16 mmol) was dissolved in methanol (5㎖) and water (2㎖), and oxone (147㎎, 0.24 mmol) was added thereto. The reaction solution was stirred for 4 hours at room temperature and then extracted with ethyl acetate. The organic layer thus separated was washed with water, dried over anhydrous magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate = 2:1) to obtain 77㎎ (yield: 77%) of the title compound as a white foam.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.01(t, 1H), 6.83(d, 1H), 6.76(d, 2H), 6.67(d, 2H), 6.6(d, 1H), 6.50(s, 1H), 6.38(d, 2H), 6.14(s, 1H), 5.90(s, 1H), 5.11(s, 1H), 4.58(d, 1H), 4.03(d, 1H), 3.90(s, 1H), 3.6(m, 2H), 3.12(m, 4H), 2.27(m, 4H), 2.08(m, 2H), 1.82(m, 2H), 1.53(s, 3H)

Example 43

Synthesis of thioacetic acid 2-piperidinoethyl ester



Potassium thioacetate (1.8g, 16.35 mmol) was added to acetone (50㎖)

and then stirred for 10 minutes under argon atmosphere. 1-(2-Chloroethyl)-piperidine (1.61g, 10.40 mmol) was added dropwise thereto and stirred for 18 hours under argon atmosphere at room temperature. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer thus separated was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified with flash column chromatography (dichloromethane:ethyl acetate = 19:1) to obtain 0.71g (yield: 35%) of the title compound as a red oil.

^{1}H-NMR($CDCl_3$) : δ 3.04(t, J=8Hz, 2H), 2.52(t, J=6Hz, 2H), 2.45(t, J=5Hz, 4H), 2.34(s, 3H), 1.60(m, 4H), 1.44(m, 2H)

Example 44

Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[9-(2-piperidinoethylthio)nonyl]-2,3-dihydro-4H-benzopyran



Thioacetic acid 2-piperidinoethyl ester (241㎎, 1.29 mmol) was dissolved in methanol (10㎖) and aqueous 2N-NaOH solution (1.5㎖) was added thereto. The mixture was stirred for one hour at room temperature. To the resulting solution was added (3RS,4RS)-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[9-(p-toluenesulfonyloxy)nonyl]-2,3-dihydro-4H-benzopyran (274㎎, 0.43 mmol) dissolved in methanol (10㎖). The reaction mixture was stirred for 2 hours at 60℃ and then cooled to room temperature. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer thus separated was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified with flash

column chromatography (n-hexane:ethyl acetate = 8:1 → dichloromethane:ethyl acetate = 19:1 → dichloromethane:ethanol = 9:1) to obtain 187㎎ (yield: 70%) of the title compound as a pale yellow oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.07(d, J=7Hz, 2H), 6.95(d, J=9Hz, 2H), 6.88(d, J=9Hz, 1H), 6.50(m, 2H), 5.11(s, 2H), 5.07(s, 2H), 4.45(d, J=10Hz, 1H), 4.20(d, J=2Hz, 1H), 3.42(s, 6H), 2.57(m, 3H), 2.50(m, 2H), 2.44(m, 3H), 2.39(m, 4H), 1.53(m, 6H), 1.38(d, J=5Hz, 2H), 1.30-1.05(m, 16H)

Example 45

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(2-piperidinoethylthio)nonyl]-2,3-dihydro-4H-benzopyran



(3RS,4RS)-7-Methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[9-(2-piperidinoethylthio)nonyl]-2,3-dihydro-4H-benzopyran (174㎎, 0.28 mmol) and methanol solution of 5N-HCl (1㎖) were dissolved in methanol (10㎖) and then stirred for 5 hours at 40℃. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer thus separated was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified with flash column chromatography (dichloromethane:ethanol = 9:1) to obtain 139㎎ (yield: 93%) of the title compound as a pale yellow oil.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 6.99(dd, J=9Hz, J=2Hz, 2H), 6.82(d, J=9Hz, 1H), 6.73(d, J=9Hz, 2H), 6.28(m, 2H), 4.43(d, J=10Hz, 1H), 4.17(d, J=2Hz, 1H), 2.85(m, 1H), 2.61(m, 3H), 2.53(m, 4H), 2.42(t, J=9Hz, 3H),

1.63(m, 5H), 1.41(m, 4H), 1.22-1.03(m, 16H)

Example 46

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-((2-piperi -dinoethyl)sulfinyl)nonyl]-2,3-dihydro-4H-benzopyran



(3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(2-piperidinoethyl -thio)nonyl]-2,3-dihydro-4H-benzopyran (126㎎, 0.24 mmol) was dissolved in methanol (5㎖) and water (1.2㎖), and $NaIO_4$ (62㎎, 0.29 mmol) was added thereto. The reaction solution was stirred for 4 hours at room temperature and then filtered. The filtrate was concentrated and the residue was purified with flash column chromatography (dichloromethane:ethanol = 13:1 → 10:1) to obtain 96㎎ (yield: 74%) of the title compound as a white foamy solid.

^{1}H-NMR(300MHz, CD_3OD) : δ 6.98(d, J=9Hz, 2H), 6.76(d, J=8Hz, 1H), 6.69(d, J=9Hz, 2H), 6.23(dd, J=8Hz, J=2Hz, 1H), 6.15(d, J=2Hz, 1H), 4.43(d, J=10Hz, 1H), 4.15(d, J=7Hz, 1H), 2.92-2.61(m, 6H), 2.51(d, J=2Hz, 1H), 2.47(m, 4H), 1.63(m, 2H), 1.51(m, 5H), 1.36(m, 4H), 1.22-1.05(m, 14H)

MS : $542(M+1)^+$

Example 47

Synthesis of 4-(3-hydroxyphenyl)-4-hydroxy-7-methoxymethyloxy-3-[4-(metho- xymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran



Under nitrogen atmosphere 3-bromomagnesium phenyl trimethylsilyl ether was prepared from 3-bromophenyl trimethylsilyl ether (629㎎, 2.1 mmol) and magnesium turning (52㎎, 2.1 mmol) in dry tetrahydrofuran (1.5㎖) and then cooled to -78℃. 7-Methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-benzopyran-4-one (250㎎, 0.7 mmol) dissolved in dry tetrahydrofuran (2㎖) was slowly added dropwise thereto and then stirred for one hour. The reaction solution was quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 4:1) to obtain 283㎎ (yield: 92%) of the title compound as a foam.

Example 48

Synthesis of 4-[3-(5-chloropentyloxy)phenyl]-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran



4-(3-Hydroxyphenyl)-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran (283㎎, 0.6 mmol), 1-bromo-5-chloropentane (598㎎, 3.2 mmol) and aqueous 2N-NaOH solution (1㎖) were dissolved in acetone (3㎖) and then refluxed for 6 hours. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 8:1) to obtain 307㎎ (yield: 94%) of the title compound as a colorless oil.

Example 49

Synthesis of 4-[3-(5-chloropentyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran



4-[3-(5-Chloropentyloxy)phenyl]-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran (307㎎, 0.56 mmol) was dissolved in methanol (15㎖), and 10% Pd/C (102㎎) was slowly added dropwise thereto. Then the reaction mixture was stirred under hydrogen atmosphere for 2 hours and filtered. The filtrate was concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 8:1) to obtain 283㎎ (yield: 95%, 3RS,4RS/3RS,4SR=1:1) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$, 3RS,4RS-compound) : δ 7.10(m, 1H), 6.78 (m, 5H), 6.70(t, 3H), 6.63(s, 1H), 6.45(d, 1H), 5.90(s, 1H), 5.15(d, 4H), 4.61 (dd, 1H), 4.20(dd, 1H), 3.83(t, 2H), 3.42(s, 3H), 3.21(s, 3H), 1.80-1.17(m, 6H)

Example 50

Synthesis of 4-[3-(5-iodopentyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran



4-[3-(5-Chloropentyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyl -oxy)phenyl]-2,3-dihydro-4H-benzopyran (283㎎, 0.5 mmol) and sodium iodide (24㎎, 1.6 mmol) were dissolved in methyl ethyl ketone (5㎖) and then refluxed for 12 hours. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 8:1) to obtain 293㎎ (yield: 94%) of the title compound as a yellow oil.

Example 51

Synthesis of 7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-4-[3-(5-(4,4,5,5,5-pentafluoropentylthio)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran



4,4,5,5,5-Pentafluoropentylthioacetate (537㎎, 2.3 mmol) was dissolved in methanol (5㎖) and aqueous 2N-NaOH solution (0.5㎖) was added thereto. The mixture was stirred for one hour at room temperature. 4-[3-(5-Iodopentyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran (293㎎, 0.47 mmol) dissolved in methanol (2㎖) was added dropwise thereto and then stirred for 2 hours at 60℃. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 8:1) to obtain 290㎎ (yield: 89%) of the title compound as a colorless oil.

Example 52

Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-4-[3-(5-(4,4,5,5,5-pentafluoropentyl-thio)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran



7-Methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-4-[3-(5-(4,4,5,5,5-pentafluoropentylthio)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran (290㎎, 0.4 mmol) and pyridinium p-toluenesulfonate (1.05g, 4 mmol) were dissolved in methanol (6㎖) and then refluxed for 8 hours. The reaction mixture was cooled to room temperature and then water was added thereto. The reaction solution was extracted with ethyl acetate and the organic layer was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The concentrate was separated by column chromatography (n-hexane:ethyl acetate = 1:1) to obtain 177㎎ (yield: 74%) of the title compound as a colorless oil.

Example 53

Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-4-[3-(5-(4,4,5,5,5-pentafluoropentyl -sulfinyl)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran



7-Hydroxy-3-(4-hydroxyphenyl)-4-[3-(5-(4,4,5,5,5-pentafluoropentylthio)pen -tyloxy)phenyl]-2,3-dihydro-4H-benzopyran (90㎎, 0.15 mmol) was dissolved in

1,4-dioxane (1.5㎖), methanol (1.5㎖) and water (0.38㎖), and $NaIO_4$ (35.5㎎, 0.16 mmol) was added dropwise thereto. The reaction solution was stirred for 8 hours at room temperature and then filtered. The filtrate was concentrated and the residue was separated by column chromatography (n-hexane:ethyl acetate = 1:1) to obtain 58㎎ (yield: 63%, 3RS,4RS/3RS,4SR= 1:1) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$, 3RS,4RS-compound) : δ 8.36(s, 1H), 7.20 (dd, 1H), 6.90(d, 1H), 6.80(t, 3H), 6.52(t, 2H), 6.40(s, 1H), 6.36(m, 2H), 5.83(s, 1H), 5.15(s, 1H), 4.43(dd, 1H), 4.25(dd, 2H), 3.80-3.40(dd, 2H), 3.22-2.70(m, 4H), 2.52-2.22(m, 4H), 2.0-1.43(m, 6H)

Example 54

Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-4-[3-(5-(4,4,5,5,5-pentafluoropentyl -sulfonyl)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran



7-Hydroxy-3-(4-hydroxyphenyl)-4-[3-(5-(4,4,5,5,5-pentafluoropentylthio)pen -tyloxy)phenyl]-2,3-dihydro-4H-benzopyran (84㎎, 0.14 mmol) was dissolved in methanol (4㎖) and water (2㎖), and oxone (262㎎, 0.4 mmol) was added dropwise thereto. The reaction solution was stirred for 1.5 hours at room temperature and, after adding water, extracted with ethyl acetate. The organic layer thus separated was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The residue was separated by column chromatography (n-hexane:ethyl acetate = 5:1)

to obtain 36mg (yield: 40%, 3RS,4RS/3RS,4SR=1:1) of the title compound as a colorless oil.

^{1}H-NMR(300MHz, $CDCl_3$, 3RS,4RS-compound) : δ 7.05(dd, 1H), 6.82(dd, 1H), 6.65(t, 3H), 6.58(d, 2H), 6.40(d, 1H), 6.26(m, 2H), 6.05(s, 1H), 5.75(s, 1H), 5.16(s, 1H), 4.36(dd, 1H), 4.15(dd, 1H), 3.40-3.31(t, 2H), 3.15-2.80(m, 4H), 2.32-2.15(t, 4H), 1.75(m, 2H), 1.71-1.45(m, 4H)

Example 55

Synthesis of 4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-4-[4-(piperidinoethyloxy)phenyl]-2,3-dihydro-4H-benzopyran



4-(4-Hydroxyphenyl)-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-2,3-dihydro-4H-benzopyran (310mg, 0.59 mmol) prepared in Example 15, [1-(2-chloroethyl)]piperidine · HCl (176mg, 0.9 mmol) and K_2CO_3 (264 mg, 1.8 mmol) were dissolved in acetone (8mℓ) and then refluxed for 62 hours. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer thus separated was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced

pressure to remove the organic solvent. The residue was separated by column chromatography (n-hexane:ethyl acetate = 1:2) to obtain 83㎎ (yield: 7%) of the title compound as a white foam.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 7.00(d, 2H), 6.78(d, 3H), 6.62(m, 4H), 6.37(dd, 2H), 5.25(d, 2H), 4.65(dd, 1H), 4.25(dd, 1H), 3.99(t, 2H), 3.38(dd, 1H), 3.31(d, 3H), 2.78(t, 2H), 2.43(m, 4H), 1.55(m, 4H), 1.35(m, 3H)

Example 56

Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-4-[4-(piperidinoethyloxy)phenyl]-2H-benzopyran



4-Hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-4-[4-(piperidinoethyloxy)phenyl]-2,3-dihydro-4H-benzopyran (83㎎, 0.14 mmol) and pyridinium p-toulenesulfonate (214㎎, 1.4 mmol) were dissolved in methanol (6 ㎖) and then refluxed for 12 hours. The reaction solution was cooled to room temperature and, after adding water, extracted with ethyl acetate. The organic layer thus separated was dried over anhydrous magnesium sulfate, filtered and then concentrated under reduced pressure to remove the organic solvent. The residue was separated by column chromatography (n-hexane:ethyl acetate = 1:4) to obtain 23㎎ (yield: 37%) of the title compound as a foam.

^{1}H-NMR(300MHz, $CDCl_3$) : δ 6.95(d, 2H), 6.78(d, 2H), 6.65-6.48(m, 5H), 6.39(d, 1H), 6.21(dd, 1H), 5.00(s, 2H), 3.99(t, 2H), 2.76(t, 2H), 2.54(m,

4H), 1.62(m, 4H), 1.43(m, 2H)

Example 57

Synthesis of 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one

The process for preparing 7-methoxy-3-(4-methoxyphenyl)-3-methyl-thiochroman-4-one described hereinafter corresponds to the process 7 depicted in the reaction scheme VII.

(1) To a solution of oxalic acid diethyl ester (18.8㎖, 0.14 mol) in tetrahydrofuran (10㎖) and benzene (10㎖) was added sodium hydride (80% oil suspension, 6.5g, 0.22 mol) and then stirred for 10 minutes under argon atmosphere. A benzene solution (100㎖) of 2-(p-methoxyphenyl)acetic acid ethyl ester (1) (27.0g, 0.14 mol) was added to the resulting solution and stirred for 3 days at room temperature. The reaction solution was quenched with aqueous 2N HCl solution and extracted with ether. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. Thus, 48.0g of the crude product was obtained. The obtained crude product was dissolved in water (150㎖) and 37% formalin (25㎖, 0.31 mol) was added dropwise thereto. To the reaction mixture was added dropwise aqueous potassium carbonate solution (24g, 0.17 mol, 100㎖) and then stirred for 24 hours. The reaction solution was extracted with ether, and the organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and distilled under reduced pressure to remove the solvent. The obtained crude product was then purified with silica gel column chromatography (ethyl acetate:hexane = 1:5) to obtain 27.0g (yield: 94%) of ethyl α-(4-methoxyphenyl)acrylate (2).

^{1}H-NMR($CDCl_3$) : δ 7.37, 6.88(4H, AA'BB', J=9Hz, Ar-H), 6.25(1H, s, olefin-H), 5.82(1H, s, olefin-H), 4.28(2H, q, J=7Hz, CO_2CH_2), 3.82(3H, s, OCH_3), 1.33(3H, t, J=7Hz, $CH_2C\underline{H}_3$)

(2) To tetrahydrofuran solution (150㎖) of ethyl α-(4-methoxyphenyl)-acrylate (2) (26.0g, 0.13 mol) obtained above and 3-methoxybenzenethiol (15.6 ㎖, 0.13 mol) was added tetrahydrofuran solution (6.24㎖, 1.0M, 6.24 mmol) of tetrabutylammoniumfluoride under argon atmosphere and then stirred for 10 minutes at room temperature. The reaction solution was distilled under reduced pressure to remove the solvent and the obtained crude product was then purified with silica gel column chromatography (ethyl acetate:hexane=1:5) to obtain 30.2g (yield: 70%) of ethyl 2-(4-methoxyphenyl)-3-(3-methoxyphenyl-thio)propionate (3).

^{1}H-NMR($CDCl_3$) : δ 7.23-7.18(3H, m, Ar-H), 6.94-6.73(5H, m, Ar-H), 4.14(2H, q, J=7Hz, CO_2CH_2), 3.79(6H, s, $OCH_3\times2$), 3.74(1H, dd, J=9, 6Hz, $CHCO_2$), 3.55(1H, dd, J=14, 9Hz, 2-H), 3.21(1H, dd, J=14, 6Hz, 2-H), 1.21(3H, t, J=7Hz, $CH_2C\underline{H}_3$)

(3) To acetone solution(300㎖) of ethyl 2-(4-methoxyphenyl)-3-(3-methoxy-phenylthio)propionate(3) (30.2g, 87.3 mmol) obtained above was added aqueous 6N-HCl solution (200㎖) and then heated under refluxing for 60 hours. The reaction solution was extracted with ether, and the organic layer was alkalized with aqueous 20% NaOH solution. Then the aqueous layer was separated, acidified with 20% HCl solution and extracted with ether. The ether layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent to obtain 25.4g (yield: 91%) of 2-(4-methoxyphenyl)-3-(3-methoxyphenylthio)propionic acid (4).

(4) To acetonitrile solution (120㎖) of 2-(4-methoxyphenyl)-3-(3-methoxy-phenylthio)propionic acid (4) (12.8g, 40.3 mmol) obtained above was added potassium carbonate (1.59g, 11.5 mmol) and phosphorus oxychloride (18.7㎖, 200 mmol) at 0℃ and then stirred for 18 hours at 60℃. The reaction solution was quenched with ice-water and extracted with ether. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The

obtained crude product was washed with ether to obtain 6.8g of the first crop of 7-methoxy-3-(4-methoxyphenyl)thiochroman-4-one (5). Further, the filtrate was concentrated and the residue was then purified with silica gel column chromatography (ethyl acetate:hexane = 1:3) to obtain 1.0g of the second crop of 7-methoxy-3-(4-methoxyphenyl)thiochroman-4-one (5) (total yield: 7.8g, 65%). NMR data of the compound (5) was identical to that described in Example 25.

The process for preparing the title compound, 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one, from the compound (5) obtained above is identical to that of Example 26.

Example 58

Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-one



To acetic acid solution (15㎖) of 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one (2.82g, 8.99 mmol) was added aqueous 48% HBr solution (13㎖) and the mixture was heated under refluxing for 24 hours. The reaction solution was extracted with ethyl acetate, and the organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate: hexane = 2:1) to obtain 2.46g (yield: 96%) of the title compound.

^{1}H-NMR(270MHz, d_6-DMSO) : δ 7.95(1H, d, J=9Hz, 5-H), 7.00, 6.65(4H, AA'BB', J=9Hz, Ar-H), 6.60(1H, dd, J=9, 2Hz, 6-H), 6.47(1H, d, J=2Hz, 8-H), 3.55(2H, ABq, J=12Hz, 2-H), 1.38(3H, s, CH_3)

Example 59

Synthesis of 7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman-4-one



To dry acetone solution (100㎖) of 7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-one (2.30g, 8.04 mmol) were added potassium carbonate (8.87g, 64.3 mmol) and methoxymethyl chloride (4.64㎖, 61.5 mmol), and the mixture was heated under refluxing for 40 hours. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate :hexane = 1:3) to obtain 2.65g (yield: 88%) of the title compound.

^{1}H-NMR($CDCl_3$) : δ 8.18(1H, d, J=9Hz, 5-H), 7.14, 6.96(4H, AA'BB', J=9Hz, Ar-H), 6.80(1H, dd, J=9, 2Hz, 6-H), 6.74(1H, d, J=2Hz, 8-H), 5.35, 5.22(each 2H, each s, $OC\underline{H}_2OCH_3$), 3.51, 3.44(each 1H, each d, J=4Hz, 2-H), 3.44(6H, s, $OCH_3\times2$), 1.47(3H, s, 3-CH_3)

Example 60

Synthesis of 4-(4-t-butyldimethylsilyloxyphenyl)-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman



Under argon atmosphere dibromoethane (0.11mℓ, 1.28 mmol) was added dropwise to tetrahydrofuran suspension (5mℓ) of magnesium turning (224mg, 9.33 mmol) and the mixture was stirred for 10 minutes at 60℃. At the same temperature, tetrahydrofuran solution (5mℓ) of p-bromo-t-butyldimethylsilyloxybenzene (2.30g, 8.01 mmol) was added dropwise thereto and the mixture was heated under refluxing for 1.5 hours. To the resulting solution was added dropwise tetrahydrofuran solution (5mℓ) of 7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman-4-one (1.00g, 2.67 mmol) and the mixture was heated under refluxing for 3 hours. After adding saturated aqueous ammonium chloride solution, the reaction solution was extracted with ethyl acetate, and the organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate:hexane = 1:4) to obtain 1.29g (yield: 83%) of the title compound.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.25-6.60(11H, m, Ar-H), 5.15, 5.14(each 2H, each s, $OC\underline{H}_2OCH_3$), 4.28(1H, d, J=12Hz, 2-H), 3.48, 3.46(each 3H, each s, $OCH_3\times2$), 2.73(1H, d, J=12Hz, 2-H), 1.45(3H, s, 3-CH_3), 0.98(9H, s, t-Bu), 0.19(6H, s, $SiCH_3\times2$)

Example 61

Synthesis of (3RS, 4RS)-4-(4-t-butyldimethylsilyloxyphenyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman



To dichloromethane solution (30㎖) of 4-(4-t-butyldimethylsilyloxyphenyl)-4-hydroxy-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman (1.134g, 1.95 mmol) were added zinc iodide (1.367g, 4.9 mmol) and sodium cyanoborohydride (797㎎, 12.7 mmol), and the resulting mixture was stirred for 2 hours at room temperature. After adding acetone (5㎖) and water, the reaction solution was extracted with dichloromethane and the organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and distilled under reduced pressure to remove the organic solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate:hexane = 1:4) to obtain 783㎎ (yield: 71%) of the title compound.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.34, 6.90(4H, AA'BB', J=9Hz, Ar-H), 7.00, 6.88(4H, AA'BB', J=8Hz, Ar-H), 6.72(1H, d, J=8Hz, 5-H), 6.71(1H, d, J=3Hz, 8-H), 6.57(1H, dd, J=8, 3Hz, 6-H), 5.12(2H, s, $OC\underline{H}_2OCH_3$), 5.06(2H, d, J=1Hz, $OC\underline{H}_2OCH_3$), 4.40(1H, s, 4-H), 3.46, 3.43(each 3H, each s, $OCH_3\times$

2), 3.22(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 1.15(3H, s, 3-CH_3), 0.97(9H, s, t-Bu), 0.18(6H, s, $SiCH_3 \times 2$)

Example 62

Synthesis of (3RS,4RS)-4-(4-hydroxyphenyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman



Under argon atmosphere, tetrahydrofuran solution of tetrabutylammonium fluoride (1.0M, 2.27mℓ, 2.27 mmol) was added dropwise to tetrahydrofuran solution (35mℓ) of (3RS,4RS)-4-(4-t-butyldimethylsilyloxyphenyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman (856mg, 1.51 mmol) at 0℃ and the resulting mixture was stirred for 2 hours. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate :hexane = 1:2) to obtain 682mg (yield: 100%) of the title compound.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.32, 6.90(4H, AA'BB', J=8Hz, Ar-H), 7.02, 6.86(4H, AA'BB', J=8Hz, Ar-H), 6.72(1H, d, J=8Hz, 5-H), 6.70(1H, d, J=3Hz, 8-H), 6.57(1H, dd, J=8, 3Hz, 6-H), 5.12(2H, s, $OC\underline{H}_2OCH_3$), 5.05(2H,

d, J=1Hz, $OC\underline{H}_2OCH_3$), 4.76(1H, brs, OH), 4.40(1H, s, 4-H), 3.46, 3.43(each 3H, each s, $OCH_3 \times 2$), 3.22(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 1.15(3H, s, 3-CH_3)

Example 63

Synthesis of 5-(5-chloropentylthio)-1,1,1,2,2-pentafluoropentane



Under argon atmosphere sodium methoxide-methanol solution (1.0M, 1.7 mℓ, 1.7 mmol) was added dropwise to methanol solution (5mℓ) of 4,4,5,5,5-pentafluoropentylthioacetate (400mg, 1.69 mmol) at room temperature and stirred for 20 minutes. To the resulting solution was added dropwise methanol solution (5mℓ) of 5-chloro-1-bromopentane (344mg, 1.86 mmol), and the mixture was stirred for 20 hours. After adding saturated aqueous sodium hydrogen carbonate solution, the reaction solution was extracted with ether. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate:hexane = 1:5) to obtain 463mg (yield: 82%) of the title compound.

^{1}H-NMR($CDCl_3$) : δ 3.54(2H, t, J=7Hz, $ClCH_2$), 2.59, 2.53(each 2H, each t, J=7Hz, CH_2SCH_2), 2.25-1.56(10H, m, alkyl-H)

Example 64

Synthesis of 5-(5-chloropentylsulfonyl)-1,1,1,2,2-pentafluoropentane



Aqueous solution (2mℓ) of oxone (865mg, 1.41 mmol) was added dropwise to tetrahydrofuran-methanol (2:1) solution (3mℓ) of 5-(5-chloropentyl-thio)-1,1,1,2,2-pentafluoropentane (210mg, 0.70 mmol) at 0℃ and stirred for 5 hours. After adding aqueous sodium thiosulfate solution, the reaction solution was extracted with ether. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with silica gel column chromatography (ethyl acetate:hexane = 1:10) to obtain 209mg (yield: 90%) of the title compound.

^{1}H-NMR($CDCl_3$) : δ 3.56(2H, t, J=7Hz, $ClCH_2$), 3.08-2.98(4H, m, $CH_2SO_2CH_2$), 2.40-1.60(10H, m, alkyl-H)

Example 65

Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[4-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentyloxy)phenyl]thiochroman



5-(5-Chloropentylsulfonyl)-1,1,1,2,2-pentafluoropentane (27mg, 0.082 mmol), potassium carbonate (34mg, 0.25 mmol) and 18-crown-6 (21mg, 0.08

mmol) were added to benzene-dimethylformamide (1:1) solution (2㎖) of (3RS,4RS)-4-(4-hydroxyphenyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman (37㎎, 0.082 mmol) and then stirred for 8 hours at 100℃ under argon atmosphere. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified using silica gel plate (ethyl acetate:hexane = 1:2) to obtain 41㎎ (yield: 67%) of the title compound.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.37, 6.90(4H, AA'BB', J=9Hz, Ar-H), 7.06, 6.85(4H, AA'BB', J=8Hz, Ar-H), 6.77(1H, d, J=9Hz, 5-H), 6.70(1H, d, J=3Hz, 8-H), 6.56(1H, dd, J=9, 3Hz, 6-H), 5.12(2H, s, $OC\underline{H}_2OCH_3$), 5.05(2H, d, J=1Hz, $OC\underline{H}_2OCH_3$), 4.41(1H, s, 4-H), 3.94(2H, t, J=7Hz, $ArOC\underline{H}_2CH_2$), 3.46, 3.42 (each 3H, each s, $OCH_3\times2$), 3.22(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 3.05-2.99(4H, m, $CH_2SO_2CH_2$), 2.38-1.60(10H, m, alkyl-H), 1.15(3H, s, 3-CH_3)

Example 66

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentyloxy)phenyl]thiochroman



Aqueous 6N-HCl solution (1㎖) was added to tetrahydrofuran solution (1.5㎖) of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-

methyl-4-[4-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentyloxy)phenyl]thiochroman (37㎎, 0.050 mmol) and then stirred for one hour. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified using silica gel plate (ethyl acetate:hexane = 1:2) to obtain 22㎎ (yield: 70%) of the title compound.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.27(2H, d, J=8Hz, Ar-H), 7.05(2H, d, J=8Hz, Ar-H), 6.79-6.68(5H, m, Ar-H), 6.48(1H, d, J=3Hz, 8-H), 6.37(1H, dd, J=9, 3Hz, 6-H), 4.62(2H, s, OH×2), 4.37(1H, s, 4-H), 3.94(2H, t, J=7Hz, $ArOC\underline{H_2}CH_2$), 3.19(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 3.10-2.98(4H, m, $CH_2SO_2CH_2$), 2.38-1.60(10H, m, alkyl-H), 1.16(3H, s, 3-CH_3)

Example 67

Synthesis of (3RS,4RS)-4-[4-(4-chlorobutyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman



To acetone solution (2㎖) of (3RS,4RS)-4-(4-hydroxyphenyl)-7-methoxy-

methyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman (70㎎, 0.15 mmol) were added 1-bromo-4-chlorobutane (36㎕, 0.31 mmol) and potassium carbonate (64㎎, 0.46 mmol), and the resulting mixture was heated under refluxing for 20 hours. After adding water, the reaction solution was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate and then distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified using silica gel plate (ethyl acetate:hexane = 1:2) to obtain 73㎎ (yield: 87%) of the title compound.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.34, 6.90(4H, AA'BB', J=9Hz, Ar-H), 7.05, 6.86(4H, AA'BB', J=9Hz, Ar-H), 6.77(1H, d, J=9Hz, 5-H), 6.70(1H, d, J=3Hz, 8-H), 6.55(1H, dd, J=8, 3Hz, 6-H), 5.12(2H, s, $OC\underline{H}_2OCH_3$), 5.05(2H, d, J=1Hz, $OC\underline{H}_2OCH_3$), 4.41(1H, s, 4-H), 3.95(2H, t, J=7Hz, $ArOC\underline{H}_2CH_2$), 3.61(2H, t, J=6Hz, $ClCH_2$), 3.45, 3.42(each 3H, each s, $OCH_3\times2$), 3.22(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 2.00-1.88(4H, m, alkyl-H), 1.15(3H, s, 3-CH_3)

Example 68

Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[4-(4-piperidinobutyloxy)phenyl]thiochroman



Piperidine (40㎕, 0.405 mmol) was added to ethanol solution (2㎖) of (3RS,4RS)-4-[4-(4-chlorobutyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman (73㎎, 0.135 mmol) and then heated under refluxing for 24 hours. The reaction solution was distilled under reduced pressure to remove the solvent. The crude product thus obtained was purified with amino silica gel chromatography (ethyl acetate:hexane = 1:5) to obtain 55 ㎎ (yield: 69%) of the title compound.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.34, 6.90(4H, AA'BB', J=9Hz, Ar-H), 7.05, 6.86(4H, AA'BB', J=9Hz, Ar-H), 6.77(1H, d, J=9Hz, 5-H), 6.70(1H, d, J=3Hz, 8-H), 6.55(1H, dd, J=8, 3Hz, 6-H), 5.11(2H, s, $OC\underline{H}_2OCH_3$), 5.05(2H, d, J=1Hz, $OC\underline{H}_2OCH_3$), 4.41(1H, s, 4-H), 3.93(2H, t, J=7Hz, $ArOC\underline{H}_2CH_2$), 3.61(2H, t, J=6Hz, $ClCH_2$), 3.45, 3.42(each 3H, each s, $OCH_3\times2$), 3.22(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 2.50-2.30(6H, m, $NCH_2\times3$), 1.85-1.35(10H, m, alkyl-H), 1.15(3H, s, 3-CH_3)

Example 69

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(4-piperidinobutyloxy)phenyl]thiochroman



To tetrahydrofuran solution (3㎖) of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-[4-(4-piperidinobutyloxy)phenyl]thiochro-man (55㎎, 0.093 mmol) was added aqueous 10% HCl solution (2㎖) and the resulting mixture was stirred for 20 hours. The reaction solution was distilled

under reduced pressure to remove the solvent. The crude product thus obtained was purified with amino silica gel chromatography (ethyl acetate) to obtain 25㎎ (yield: 53%) of the title compound.

^{1}H-NMR(270MHz, CD_3OD) : δ 7.29(2H, d, J=9Hz, Ar-H), 7.08(2H, d, J=8Hz, Ar-H), 6.78(2H, d, J=9Hz, Ar-H), 6.73(1H, d, J=8Hz, Ar-H), 6.62(2H, d, J=8Hz, Ar-H), 6.40(1H, t, J=2Hz, 8-H), 6.30(1H, dd, J=8, 2Hz, 6-H), 4.40(1H, s, 4-H), 3.95(2H, t, J=7Hz, $ArOCH_2CH_2$), 3.31(2H, s, OH×2), 3.12(2H, s, 2-H), 2.50-2.30(6H, m, $NCH_2\times3$), 1.85-1.35(10H, m, alkyl-H), 1.11(3H, s, 3-CH_3)

Example 70

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(4-piperidinobutyloxy)phenyl]thiochroman hydrochloride



To methanol solution (3㎖) of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl) -3-methyl-4-[4-(4-piperidinobutyloxy)phenyl]thiochroman (18㎎, 0.093 mmol) was added aqueous 20% HCl solution (0.3㎖) and the resulting mixture was stirred for 20 hours. The reaction solution was distilled under reduced pressure to remove the solvent and the crude product thus produced was dissolved in methanol. To the resulting solution was added Dowex 1-×8 (240㎎) and the mixture was stirred for 30 minutes. Dowex 1-×8 was filtered off and the filtrate was then distilled under reduced pressure to remove the solvent. To the residue were added toluene (0.5㎖), methanol (0.5㎖) and 35% HCl (0.5㎖)

and the mixture was distilled under reduced pressure to obtain 17㎎ (yield: 96%) of the title compound.

^{1}H-NMR(270MHz, CD_3OD) : δ 7.30(2H, d, J=9Hz, Ar-H), 7.11(2H, d, J=8Hz, Ar-H), 6.81(2H, d, J=9Hz, Ar-H), 6.73(1H, d, J=8Hz, Ar-H), 6.63(2H, d, J=8Hz, Ar-H), 6.40(1H, t, J=2Hz, 8-H), 6.29(1H, dd, J=8, 2Hz, 6-H), 4.42(1H, s, 4-H), 4.01(2H, t, J=7Hz, $ArOC\underline{H}_2CH_2$), 3.60-3.40(2H, m, NCH_2), 3.12(4H, brs, $NCH_2\times2$), 2.00-1.70(10H, m, alkyl-H), 1.11(3H, s, 3-CH_3)

Example 71

Synthesis of 1-(4,4,5,5,5-pentafluoropentyl)piperazine



Piperazine (777㎎, 9.0 mmol) was added to ethanol solution (10㎖) of 4,4,5,5,5-pentafluoropentyloxytoluenesulfonate (600㎎, 1.81 mmol) and then heated under refluxing for 40 hours. After adding water, the reaction solution was extracted with ethyl acetate. The solvent was distilled off under reduced pressure from the extract to obtain 315㎎ (yield: 100%) of the title compound.

^{1}H-NMR($CDCl_3$) : δ 2.89(4H, t, J=5Hz, $C\underline{H}_2NH\times2$), 2.38(6H, m, $NCH_2\times3$), 2.20-1.95(2H, m, CF_2CH_2), 1.83-1.70(2H, m, $CF_2CH_2C\underline{H}_2$)

Example 72

Synthesis of (3RS,4RS)-4-[4-(2-chloroethyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman



To methyl ethyl ketone solution (3㎖) of (3RS,4RS)-4-(4-hydroxyphenyl) -7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-thiochroman (126 ㎎, 0.28 mmol) were added potassium carbonate (96㎎, 0.70 mmol) and 1-bromo-2-chloroethane (115㎖, 1.38 mmol), and the mixture was heated under refluxing for 70 hours. After adding water, the reaction solution was extracted with ethyl acetate. The extract was distilled under reduced pressure to remove the solvent and the crude product thus obtained was then purified using silica gel plate (ethyl acetate:hexane = 1:2) to obtain 69㎎ (yield: 48%) of the title compound.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.34, 6.90(4H, AA'BB', J=9Hz, Ar-H), 7.08, 6.81(4H, AA'BB', J=9Hz, Ar-H), 6.89(1H, d, J=8Hz, 5-H), 6.71(1H, d, J=3Hz, 8-H), 6.55(1H, dd, J=8, 3Hz, 6-H), 5.12(2H, s, $OC\underline{H}_2OCH_3$), 5.05(2H, d, J=1Hz, $OC\underline{H}_2OCH_3$), 4.42(1H, s, 4-H), 4.19(2H, t, J=6Hz, $ArOCH_2$), 3.79(2H, t, J=6Hz, $ClCH_2$), 3.45, 3.43(each 3H, each s, $OCH_3\times2$), 3.20(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 1.15(3H, s, 3-CH_3)

Example 73

Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-{4-[2-(4-(4,4,5,5,5-pentafluoropentyl)piperazino)ethyloxy]phenyl}thio

-chroman



Under argon atmosphere 4-(4,4,5,5,5-pentafluoropentyl)piperazine (70㎎, 0.4 mmol) was added to dimethylformamide solution (0.5㎖) of (3RS,4RS)-4-[4-(2-chloroethyloxy)phenyl]-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl] -3-methyl-thiochroman (69㎎, 0.13 mmol) and then stirred for 8 hours at 80℃. After adding water, the reaction solution was extracted with ethyl acetate. The extract was distilled under reduced pressure to remove the solvent and the crude product thus obtained was then purified using amino silica gel plate (ethyl acetate:hexane = 1:2) to obtain 67㎎ (yield: 77%) of the title compound.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.33, 6.90(4H, AA'BB', J=9Hz, Ar-H), 7.05, 6.79(4H, AA'BB', J=9Hz, Ar-H), 6.86(1H, d, J=8Hz, 5-H), 6.70(1H, d, J=3Hz, 8-H), 6.55(1H, dd, J=8, 3Hz, 6-H), 5.11(2H, s, $OC\underline{H}_2OCH_3$), 5.05(2H, d, J=1Hz, $OC\underline{H}_2OCH_3$), 4.41(1H, s, 4-H), 4.06(2H, t, J=6Hz, $ArOCH_2$), 3.45, 3.42(each 3H, each s, $OCH_3\times2$), 3.22(1H, d, J=13Hz, 2-H), 3.09(1H, d, J=13Hz, 2-H), 2.80(2H, t, J=6Hz, $OCH_2C\underline{H}_2$), 2.60, 2.59(each 4H, each brs, $NC\underline{H}_2C\underline{H}_2N\times2$), 2.40(2H, t, J=7Hz, NCH_2), 2.20-1.95(2H, m, CF_2CH_2), 1.85-1.70(2H, m, $CF_2CH_2CH_2$), 1.15(3H, s, 3-CH_3)

Example 74

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{4-[2-(4-(4,4,5,5,5-pentafluoropentyl)piperazino)ethyloxy]phenyl}thiochroman dihydrochloride



To methanol solution (1㎖) of (3RS,4RS)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methyl-4-{4-[2-(4-(4,4,5,5,5-pentafluoropentyl)piperazino)ethyloxy]phenyl}thiochroman (67㎎, 0.10 mmol) was added aqueous 20% HCl solution (0.5㎖) and the resulting mixture was then stirred for 20 hours at room temperature. The solvent was distilled off under reduced pressure to obtain the crude product which was then purified using amino silica gel plate (ethyl acetate:methanol= 10:1). After adding aqueous 20% HCl solution to the product, the solvent was distilled off under reduced pressure to obtain 62㎎ (yield: 85%) of the title compound.

^{1}H-NMR(270MHz, CD_3OD) : δ 7.30, 6.93(4H, AA'BB', J=9Hz, Ar-H), 7.09, 6.62(4H, AA'BB', J=9Hz, Ar-H), 6.72(1H, d, J=9Hz, 5-H), 6.40(1H, d, J=3Hz, 8-H), 6.30(1H, dd, J=8.2Hz, 6-H), 4.46(1H, s, 4-H), 4.39(2H, brs,

$ArOCH_2CH_2$), 3.90-3.60(10H, d, $NCH_2 \times 5$), 3.31(2H, m, NCH_2), 3.12(2H, ABq, J=13Hz, 2-H), 2.40-2.00(4H, m, CF_2CH_2), 1.12(3H, s, 3-CH_3)

Example 75

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfinyl)octyl]thiochroman



The title compound was prepared from 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one and 8-t-butyldimethylsilyloxyoctyne according to the same method as Examples 25 to 34.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.22(d, J=8.6Hz, 2H, Ar-H), 6.86(d, J=8.3Hz, 3H, Ar-H and C5-H), 6.67(d, J=2.3Hz, 1H, C8-H), 6.50(dd, J=2.3Hz and 8.3Hz, 1H, C6-H), 3.65(d, J=11.6Hz, 1H, C2-H), 2.94(d, J=11.6Hz, 1H, C2-H), 2.90-2.50(m, 5H, $2 \times CH_2S(O)$ and C4-H), 2.40-2.10(m, 4H, $CH_2CH_2CF_2$ -CF_3), 1.66(m, 2H, alkyl-H), 1.21(s, 3H, C3-CH_3), 1.45-0.90(m, 12H, alkyl-H)

Example 76

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[10-(4,4,5,5,5-pentafluoropentylsulfinyl)decyl]thiochroman



The title compound was prepared from 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one and 10-t-butyldimethylsilyloxydecyne according to the same method as Examples 25 to 34.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.21(d, J=8.6Hz, 2H, Ar-H), 6.86(m, 3H, Ar-H and C5-H), 6.69(s, 1H, C8-H), 6.51(d, J=6.9Hz, 1H, C6-H), 3.63(d, J=11.2Hz, 1H, C2-H), 2.94(d, J=11.2Hz, 1H, C2-H), 2.90-2.60(m, 5H, 2× $CH_2S(O)$ and C4-H), 2.40-2.10(m, 4H, $CH_2CH_2CF_2CF_3$), 1.90-1.70(m, 2H, alkyl-H), 1.17(s, 3H, C3-CH_3), 1.50-0.90(m, 16H, alkyl-H)

Example 77

Synthesis of (3RS,4RS)-7-hydroxy-3-phenyl-3-methyl-4-[9-(4,4,5,5,5-pentafluoro-pentylsulfinyl)nonyl]thiochroman



The title compound was prepared from 7-methoxy-3-phenyl-3-methylthiochroman-4-one and 9-t-butyldimethylsilyloxynonyne according to the same method as Examples 25 to 34.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.39-7.33(m, 5H, Ar-H), 6.89(d, J=7.9Hz, 1H, C5-H), 6.69(s, 1H, C8-H), 6.58-6.48(m, 2H, C6-H and ArOH), 3.68(d, J=11.5Hz, 1H, C2-H), 3.01(d, J=11.5Hz, 1H, C2-H), 2.90-2.60(m, 5H, 2 × $CH_2S(O)$ and C4-H), 2.40-2.10(m, 4H, $CH_2CH_2CF_2CF_3$), 1.67(m, 2H, alkyl-H), 1.26(s, 3H, C3-CH_3), 1.50-0.90(m, 14H, alkyl-H)

Example 78

Synthesis of (3RS,4RS)-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-penta-

fluoropentylsulfinyl)nonyl]thiochroman



The title compound was prepared from 3-(4-methoxyphenyl)-3-methylthio -chroman-4-one and 9-t-butyldimethylsilyloxynonyne according to the same method as Examples 25 to 34.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.24-6.81(m, 8H, Ar-H), 3.67(m, 1H, C2-H), 2.97(m, 1H, C2-H), 2.82-2.63(m, 5H, 2×C$\underline{H}_2$S(O) and C4-H), 2.40-2.10(m, 4H, C$\underline{H}_2$C$\underline{H}_2$$CF_2CF_3$), 1.78(m, 2H, alkyl-H), 1.40-0.80(m, 17H, alkyl-H and C3-CH_3)

Example 79

Synthesis of 7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-(9-pentylthiononyl) -thiochroman



To a solution of pentylthioacetate (430㎎, 2.94 mmol) in methanol (10 ㎖) was added dropwise 1M solution of sodium methanolate (2.52㎖, 2.52 mmol) at room temperature and stirred for one hour. A solution of 7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-(9-methanesulfonyloxynonyl)thiochroman (204㎎, 0.391 mmol) in tetrahydrofuran (5㎖) was added dropwise to the

reaction mixture at the same temperature and stirred for overnight. The reaction mixture was quenched with water and then diluted with ethyl acetate. The organic layer was separated, washed with saturated NaCl solution, dried over magnesium sulfate, filtered and then concentrated. The concentrate was subjected to flash silica gel chromatography (hexane:ethyl acetate = 9:1) to obtain 230㎎ (yield: 95%, 3RS,4RS/3RS,4SR = 9:1) of the title compound as a yellow oil.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.29(d, J=8.9Hz, 2H, Ar-H), 6.91(m, 3H, Ar-H), 6.79(d, J=2.6Hz, 1H, C8-H), 6.58(dd, J=8.2Hz and 2.6Hz, 1H, Ar-H), 3.82(s, 3H, OCH_3), 3.78(s, 3H, OCH_3), 3.64(d, J=11.2Hz, 1H, C2-H), 2.98(d, J=11.6Hz, 1H, C2-H), 2.74(brt, 1H, C4-H), 2.47(m, 4H, $2\times SCH_2$), 1.55-0.89(m, 28H, C3-CH_3 and alkyl-H)

Example 80

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentyl-thiononyl)thiochroman



To a solution of 7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-(9-pentyl-thiononyl)thiochroman (230㎎, 0.435 mmol) in dry dichloromethane (20㎖) was added dropwise 1M solution of boron tribromide in dichloromethane (3.04㎖, 3.04 mmol) at -78℃ and stirred at the same temperature for one hour. Then the reaction mixture was warmed to room temperature and stirring was continued for additional 10 hours. The reaction mixture was quenched with water and then diluted with ethyl acetate. The organic layer was washed with saturated sodium hydrogen sulfide solution and water, dried over

magnesium sulfate, filtered and evaporated. The concentrate was subjected to flash silica gel chromatography (hexane:ethyl acetate = 9:1) to obtain 178㎎ (yield: 82%) of the title compound as a colorless oil.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.23(d, J=8.6Hz, 2H, Ar-H), 6.84(dd, J=8.3Hz and 8.5Hz, 3H, Ar-H), 6.67(d, J=2.6Hz, 1H, C8-H), 6.50(dd, J=8.3Hz and 2.3Hz, 1H, Ar-H), 5.12(brs, 1H, OH), 4.83(brs, 1H, OH), 3.62(d, J=11.5Hz, 1H, C2-H), 2.95(d, J=11.5Hz, 1H, C2-H), 2.68(brt, 1H, C4-H), 2.49(m, 4H, $2\times SCH_2$), 1.58-0.89(m, 28H, C3-CH_3 and alkyl-H)

Example 81

Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentyl-sulfinylnonyl)thiochroman



A solution of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentylthiononyl)thiochroman (178㎎, 0.355 mmol) and sodium periodate (83㎎, 0.390 mmol) in methanol (20㎖) and water (5㎖) was stirred at room temperature for 3.5 hours. The reaction mixture was quenched with water and then diluted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate, filtered and concentrated. The concentrate was purified with preparative chromatography on silica gel plate (hexane:ethyl acetate = 1:1) to obtain 101㎎ (yield: 55%) of the title compound as a colorless oil.

^{1}H-NMR(270MHz, $CDCl_3$) : δ 7.24(m, 3H, Ar-H), 6.86(dd, J=8.4Hz and 2.4Hz, 2H, Ar-H), 6.66(d, J=2.3Hz, 1H, C8-H), 6.51(m, 1H, Ar-H), 5.67(s,

1H, OH), 5.43(s, 1H, OH), 3.62(dd, J=11.5Hz and 3.9Hz, 1H, C2-H), 2.76(m, 5H, C2-H and 2×S(O)CH_2), 1.71(m, 3H, alkyl-H), 1.42-0.90(m, 25H, C3-CH_3 and alkyl-H)

Example 82

Optical resolution of rac-(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman and synthesis of its sulfinyl derivative



The racemate of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman (205㎎) was separated by preparative HPLC using a Chiralcel OD (2×25㎝, available from Daicel Chemical Industries, LTD) and a UV detector at 280㎚. The eluent was a (85:12:3:0.2) mixture of n-hexane/isopropanol/methanol/trifluoroacetic acid at flow rate of 9.0㎖/min. The first eluted peak was, after evaporation of the solvent, the (-)-compound (Compound A, retention time: 19.0 min., 78.9㎎, 84.3%ee) and the second was the (+)-compound (Compound B, retention time: 21.2 min., 64.9㎎, 84.4%ee). Additionally the obtained (-) and (+)-compounds were purified by preparative HPLC under the same condition as in the first separation to give 47.6㎎ of Compound A [95.8%ee, $[a]_D$ = -18.39 (c=1.000, $CHCl_3$)] and 34.5㎎ of Compound B [96.8%ee, $[a]_D$ = +16.80 (c=1.000, $CHCl_3$)], respectively.



Compounds A and B

Compound C (from A)
Compound D (from B)

The obtained optically active Compounds A and B were oxidized to the corresponding sulfinyl Compound C (18.8㎎, yield: 38% from 47.8㎎ of Compound A) and Compound D (9.8㎎, yield: 29% from 34.5㎎ of Compound B) in a similar manner to Example 34.

Experiment 1 : Cell growth inhibiting activity

In this experiment, the cell growth inhibiting activity was determined by using the compounds of Examples 6, 7, 12 and 46 as the test compound and the known anti-estrogenic compound ZM189154 having the following structure (see, EP0124369 B1) as the control compound, according to the method described hereinafter.



ZM189154

MCF-7 cell lines (ATCC) were incubated in MEM (minimum essential medium) medium which is supplemented by 3% DCC (dextran coated charcoal)-treated FBS (fetal bovine serum) but does not contain phenol red, for one week. One day before drug administration, incubated MCF-7 cells were plated in 96-well plate in the concentration of 5×10^3 cells per well. After

the 96-well plate was incubated for one day, 0.1nM of estradiol and the test compound in the given concentration were added to each well. The plate was incubated for 7 days at 37℃ and then MTT solution (Sigma) was added to each well in the amount of 15㎕ and allowed to react for 2 hours at 37℃. After the reaction is completed, the solubilizing/stopping solution (constitution: SDS, acetic acid, N,N-dimethylformamide) was added to each well in the amount of 100㎕. Then, the absorption for each well at 570㎚ was measured by means of a plate reader. IC_{50} value for inhibiting cell growth of 50% was calculated from the results as measured and described in the following Table 1.

Table 1. IC_{50} value of the test compounds (nM)

Test compound	Compound of Example 6	Compound of Example 7	Compound of Example 12	Compound of Example 46	ZM189154
IC_{50} (nM)	277	54.8	524	33	77

From the results described in the above Table 1, it could be seen that the compound of the present invention exhibits cell growth inhibiting activity comparable to that of ZM189154 which has been known as anti-estrogenic compound in the prior art.

Experiment 2 : Anti-estrogenic activity (subcutaneous administration)

Anti-estrogenic activity of the test compound by subcutaneous administration was determined according to the method described hereinafter. In this experiment, the compounds of Examples 6, 7, 12 and 46 were used as the test compound and the known anti-estrogenic compound ZM189154 was used as the control compound as in Experiment 1.

The anti-estrogenic activity was determined by subcutaneously injecting

17β-estradiol-benzoate (Sigma) to mice (ICR, weight 30±2g), which were ovariectomized two weeks before, in an amount of 0.1μg/day, per mouse for 3 days and then measuring the degree that the test compound inhibits the increase of uterine weight. In this experiment, the test compound or the control compound was dissolved in peanut oil (Sigma) and injected subcutaneously for 3 days, once a day. After 24 hours from the last injection, the test animal was sacrificed and uterus was removed and weighed. The results as measured are described in the following Table 2.

Table 2.

Anti-estrogenic activity of the test compound in ovariectomized mice which were administered with 17β-estradiol

Test compound/dosage (s.c., 3 days)		Inhibition (%)
Compound of Example 6	30μg/mouse	83.1
Compound of Example 7	30μg/mouse	87.0
Compound of Example 12	30μg/mouse	74.8
Compound of Example 46	30μg/mouse	16.7
Control compound ZM189154	30μg/mouse	73.8

From the results described in the above Table 2, it could be seen that the compounds of Examples 6, 7, 12 and 46 according to the present invention substantially inhibit the increase of uterine weight by estradiol to the degree rather superior to that of ZM189154 which has been known as anti-estrogenic compound in the prior art.

Experiment 3 : Anti-estrogenic activity (oral administration)

Oral anti-estrogenic activity of the test compound was determined according to the method described hereinafter. In this experiment, the compound of Example 7 was used as the test compound and the known anti-estrogenic compound ZM189154 was used as the control compound as in Experiment 2.

Anti-estrogenic activity was determined by subcutaneous administration of 17-estradiol-benzoate (Sigma) to mice (ICR, weight 30±2g), which were ovariectomized 2 weeks before, in the amount of 0.1㎍/day, per mouse for 3 days and then measuring the degree that the test compound inhibits the increase in uterus weight by stimulus with estradiol. In this experiment, the test compound or the control compound was suspended in 5% arabic gum solution and orally administered for 3 days, once a day. After 24 hours from the last administration, the test animal was sacrificed and uterus was removed and weighed. The results as measured are described in the following Table 3.

Table 3.

Anti-estrogenic activity of the test compound in ovariectomized mice which were administered with 17β-estradiol (oral administration, 3 days)

Test compound/dosage (p.o., 3 days)		Inhibition (%)
Compound of Example 7	10㎎/kg	68.1
ZM189154	10㎎/kg	41.7

From the results described in the above Table 3, it could be seen that the compound according to the present invention administered via oral route substantially inhibits the increase of uterine weight by estradiol to the degree superior to that of ZM189154 which has been known as anti-estrogenic active

compound in the prior art.

Experiment 4 : Effect on bone mineral density of mouse femur

The effect of the compound of the present invention on bone mineral density of mouse femur was determined according to the method described hereinafter. In this experiment, the compounds of Example 7 was used as the test compound and the known anti-estrogenic compound ZM189154 was used as the control compound as in Experiment 2.

MCF-7 cells (ATCC) as human breast cancer cell were transplanted subcutaneously into BALB/c nude mouse (female, 6 weeks) and then estradiol was percutaneously injected twice a week in an amount of 0.01㎎/mouse, for 3 weeks. Thereafter, estradiol was administered once a week in the same amount and the test compound or the control compound dissolved in 10% ethanol-90% peanut oil was administered. The control group received only vehicle. The test or control compound was administered subcutaneously in an amount of 1㎎/0.1㎖/mouse, once a week. After the administration of the test compound for 6 weeks, left femur was excised and soft tissue was removed therefrom. Then the bone mineral density (BMD) was measured in a SPA mode by means of dual energy X-ray absorptiometry DCS-600 (Aloka). For interpretation, femur was divided into ten in the direction of long axis and the mean bone marrow densities of 3, 4 and 3 fragments from proximal position were calculated. Each of the fragments was represented as proximal, middle or distal, respectively. The result as measured is described in the following Table 4.

Table 4.

Effect of the compound of the present invention on bone mineral density of mouse femur

	proximal BMD[a]	distal BMD	whole BMD
Control group	35.95±1.50[b]	37.80±1.75	35.63±0.97
Compound of Example 7	35.05±2.05	36.29±1.46	37.23±1.41
ZM189154	34.19±2.19	32.80±1.30	34.57±1.40

* a : mg/㎠ , b : mean±SE

It is generally agreed that we focus on proximal and distal portion for elucidating the effect of anti-estrogen on bone metabolism. As can be seen from the results described in the above Table 4, the compound according to the present invention did little affect bone mineral density (BMD) at both proximal and distal portion and increased whole BMD by 4.5% when compared to control. In contrast, ZM189154 decreased BMD by 4.9%, 13.3% and 3.0% at proximal, distal and whole femur, respectively. There was no difference in inhibition of MCF-7 tumor growth between the test compound and ZM189154. Therefore, it could be identified that the compound of the present invention has little affect on BMD different from ZM189154 which has been known as anti-estrogenic active compound in the prior art.

WHAT IS CLAIMED IS :

1. A benzopyran derivative represented by formula (I):



(I)

and pharmaceutically acceptable salt thereof, in which

⁼⁼⁼⁼⁼ represents a single bond or a double bond;

R_1 and R_2 independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl;

R_3 represents hydrogen, lower alkyl or halogeno lower alkyl, provided that when ⁼⁼⁼⁼⁼ represents a double bond, R_3 is not present;

R_4 represents hydrogen or lower alkyl;

A represents a group of formula (a), (b), (c) or (d);

(a)



(b)



(c)



(d)

R_5, R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5;

X represents O, S or NR_8, wherein R_8 represents hydrogen or lower alkyl;

m denotes an integer of 2 to 15;
n denotes an integer of 0 to 2; and
p denotes an integer of 0 to 4.

2. The benzopyran derivative of formula (I) as defined in claim 1, wherein ----- represents a single bond or a double bond; R_1 and R_2 independently of one another represent hydrogen, hydroxy or OR wherein R represents alkyl; R_3 represents hydrogen, C_1-C_4 lower alkyl or halogeno-C_1-C_4 lower alkyl, provided that when ----- represents a double bond, R_3 is not present; R_4 represents hydrogen or C_1-C_4 lower alkyl; A represents a group of formula (a), (b), (c) or (d); R_5, R_6 and R_7 independently of one another represent hydrogen, C_1-C_6 alkyl, halogeno-C_1-C_6 alkyl, C_2-C_6 alkenyl or halogeno-C_2-C_6 alkenyl, or R_6 and R_7 together with nitrogen atom to which they are bound can form a 5- to 6-membered heterocyclic ring which can contain 1 to 2 nitrogen atoms and can be substituted with halogeno-C_1-C_6 alkyl; X represents O, S or NR_8, wherein R_8 represents hydrogen or C_1-C_4 lower alkyl; m denotes an integer of 4 to 12; n denotes an integer of 0 to 2 and p denotes an integer of 1 to 3.

3. The benzopyran derivative of formula (I) as defined in claim 2, wherein ----- represents a single bond or a double bond; R_1 and R_2 independently of one another represent hydrogen or hydroxy; R_3 represents hydrogen or C_1-C_2 lower alkyl, provided that when ----- represents a double bond, R_3 is not present; R_4 represents hydrogen or C_1-C_2 lower alkyl; A represents a group of formula (a), (b), (c) or (d); R_5, R_6 and R_7 independently of one another represents hydrogen, C_1-C_6 alkyl or halogeno-C_1-C_6 alkyl, or R_6 and R_7 together with nitrogen atom to which they are bound can form piperazinyl or piperidino group which can be substituted with halogeno-C_1-C_6 alkyl; X represents O or S; m denotes an integer of 4 to

12; n denotes an integer of 0 to 2 and p denotes an integer of 2.

4. The benzopyran derivative of formula (I) as defined in claim 3, wherein X represents S.

5. The benzopyran derivative of formula (I) as defined in claim 1, which is selected from the group consisting of:

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylthio)octyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfinyl)octyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfonyl)nonyl]-2,3-dihydro-4H-benzopyran;

7-hydroxy-3-(4-hydroxyphenyl)-4-[4-(5-(4,4,5,5,5-pentafluoropentylthio)pentyloxy)-phenyl]-2H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-thiochroman;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylthio)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylsulfinyl)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(4-(4,4,5,5,5-pentafluoropentylsulfonyl)butyloxy)phenyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(2-piperidinoethylthio)-nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(2-piperidinoethylsulfinyl)-nonyl]-2,3-dihydro-4H-benzopyran;

(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(5-(4,4,5,5,5-pentafluoro-

pentylthio)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(5-(4,4,5,5,5-pentafluoropentylsulfinyl)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[3-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentyloxy)phenyl]-2,3-dihydro-4H-benzopyran;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(piperidinoethyloxy)phenyl]-2,3-dihydro-4H-benzopyran;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(5-(4,4,5,5,5-pentafluoropentylsulfonyl)pentyloxy)phenyl]thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(4-piperidinobutyloxy)-phenyl]thiochroman or its hydrochloride;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{4-[2-(4-(4,4,5,5,5-pentafluoropentyl)piperazino)ethyloxy]phenyl}thiochroman dihydrochloride;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfinyl)octyl]thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[10-(4,4,5,5,5-pentafluoropentylsulfinyl)decyl]thiochroman;
(3RS,4RS)-7-hydroxy-3-phenyl-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]thiochroman;
(3RS,4RS)-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]thiochroman;
(3RS,4RS)-7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-(9-pentylthiononyl)thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentylthiononyl)thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-pentylsulfinynonyl)thiochroman;
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman; and
(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman.

6. A process for preparing the compound of formula (I):



(I)

and salt thereof, in which

⚌ represents a single bond or a double bond;

R_1 and R_2 independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl;

R_3 represents hydrogen, lower alkyl or halogeno lower alkyl, provided that when ⚌ represents a double bond, R_3 is not present;

R_4 represents hydrogen or lower alkyl;

A represents a group of formula (a), (b), (c) or (d);



(a)



(b)



(c)



(d)

R_5, R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5;

X represents O, S or NR_8, wherein R_8 represents hydrogen or lower alkyl;

m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and

p denotes an integer of 0 to 4,

characterized in that a compound of formula (VIII):



(VIII)

wherein R_3, R_4 and X are defined as above and P represents hydrogen or protected hydroxy group , is reacted with a compound of formula (IX):



(IX)

wherein q denotes an integer of m-2 and TBS means t-butyldimethylsilyl group, to produce a compound of formula (VII):



(VII)

wherein R_3, R_4, X, P, q and TBS are defined as above, the resulting compound of formula (VII) is reduced with sodium cyanoborohydride ($NaBH_3CN$) and zinc iodide (ZnI_2) to produce a compound of formula (VIA):



(VIA)

wherein ----- , R_3, R_4, X, P, q and TBS are defined as above, the resulting compound of formula (VIA) is reduced with palladium on carbon (Pd/C) to produce a compound of formula (VIB):



(VIB)

wherein ----- , R_3, R_4, X, P, m and TBS are defined as above, the resulting compound of formula (VIB) is then treated with pyridinium p-toluenesulfonate to produce a compound of formula (VIC):



(VIC)

wherein ----- , R_3, R_4, X, P and m are defined as above, the resulting compound of formula (VIC) is reacted with a compound of formula (V):

$$R_9SO_2Cl \qquad (V)$$

wherein R_9 represents methyl or tolyl, to produce a compound of formula (IV):



(IV)

wherein ----- , R_3, R_4, X, P, m and R_9 are defined as above, the compound of formula (IV) is reacted with a compound of formula (III):



(III)

wherein W represents R_5 or  , wherein R_5, R_6, R_7, n and p are defined as in formula (I), to produce a compound of formula (II):



(II)

wherein ----- , R_3, R_4, X, W, P, m and n are defined as above, and the resulting compound of formula (II) is deprotected to produce a compound of formula (Ia):



(Ia)

wherein ----- , R_3, R_4, X, W, m and n are defined as above, or the resulting compound of formula (Ia) is esterified or alkylated to produce a compound of formula (Ib):



(Ib)

wherein ----- , R, R_3, R_4, X, W, m and n are defined as above.

7. A process for preparing the compound of formula (I):



(I)

and salt thereof, in which

$\overline{\overline{\cdots}}$ represents a single bond or a double bond;

R_1 and R_2 independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl;

R_3 represents hydrogen, lower alkyl or halogeno lower alkyl, provided that when $\overline{\overline{\cdots}}$ represents a double bond, R_3 is not present;

R_4 represents hydrogen or lower alkyl;

A represents a group of formula (a), (b), (c) or (d);



(a)



(b)



(c)



(d)

R_5, R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5;

X represents O, S or NR_8, wherein R_8 represents hydrogen or lower alkyl;

m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and

p denotes an integer of 0 to 4,

characterized in that a compound of formula (VIII):



(VIII)

wherein R_3, R_4 and X are defined as above and P represents hydrogen or protected hydroxy group, is reacted with a compound of formula (XIV):



(XIV)

wherein TMS means trimethylsilyl group, to produce a compound of formula (XIII):



(XIII)

wherein R_3, R_4, X and P are defined as above, the resulting compound of formula (XIII) is reacted with a compound of formula (XII):

$$Z(CH_2)mY \qquad \text{(XII)}$$

wherein Z represents halogen, Y represents halogen or hydroxy and m is defined as above, to produce a compound of formula (XI):



(XI)

wherein R_3, R_4, X, P, Y and m are defined as above, the resulting compound of formula (XI) is reacted with a compound of formula (IIIa):



(IIIa)

wherein R_5 and n are defined as above, to produce a compound of formula (X):



(X)

wherein R_3, R_4, R_5, X, P, m and n are defined as above, and the resulting compound of formula (X) is deprotected to produce a compound of formula (Ic):



(Ic)

wherein ----- , R_3, R_4, R_5, X, m and n are defined as above, or the resulting compound of formula (Ic) is esterified or alkylated to produce a

compound of formula (Id):



(Id)

wherein ═══ , R, R_3, R_4, R_5, X, m and n are defined as above.

8. A process for preparing the compound of formula (I):



(I)

and salt thereof, in which

═══ represents a single bond or a double bond;

R_1 and R_2 independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl;

R_3 represents hydrogen, lower alkyl or halogeno lower alkyl, provided that when ═══ represents a double bond, R_3 is not present;

R_4 represents hydrogen or lower alkyl;

A represents a group of formula (a), (b), (c) or (d);



(a)



(b)



(c)



(d)

R_5, R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5;

X represents O, S or NR_8, wherein R_8 represents hydrogen or lower alkyl;

m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and

p denotes an integer of 0 to 4,

characterized in that a compound of formula (XI):



(XI)

wherein R_3, R_4, X and m are defined as above, Y represents halogen or hydroxy and P represents hydrogen or protected hydroxy group, is reacted with a compound of formula (XVI):

(XVI)

wherein R_6 and R_7 are defined as above, to produce a compound of formula (XV):



(XV)

wherein R_3, R_4, R_6, R_7, X, P and m are defined as above, and the resulting compound of formula (XV) is deprotected to produce a compound of formula (Ie):



(Ie)

wherein ----- , R_3, R_4, R_6, R_7, X and m are defined as above, or the resulting compound of formula (Ie) is esterified or alkylated to produce a compound of formula (If):



(If)

wherein ----- , R, R_3, R_4, R_6, R_7, X and m are defined as above.

9. A process for preparing the compound of formula (Ig):



(Ig)

and salt thereof, in which

R_3 represents hydrogen, lower alkyl or halogeno lower alkyl;

R_4 represents hydrogen or lower alkyl;

W represents R_5 or  ;

R_5, R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5;

X represents O, S or NR_8, wherein R_8 represents hydrogen or lower alkyl;

m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and

p denotes an integer of 0 to 4,

characterized in that a compound of formula (VIII):



(VIII)

wherein R_3, R_4 and X are defined as above and P represents hydrogen or protected hydroxy group, is reacted with a compound of formula (XVI):



(XVI)

wherein TBS means t-butyldimethylsilyl group, to produce a compound of formula (XVII):



(XVII)

wherein R_3, R_4, X, P and TBS are defined as above, the resulting compound of formula (XVII) is reduced to produce a compound of formula (XVIII):



(XVIII)

wherein R_3, R_4, X, P and TBS are defined as above, the resulting compound of formula (XVIII) is deprotected to produce a compound of formula (XIX):



(XIX)

wherein R_3, R_4, X and P are defined as above, the resulting compound of formula (XIX) is reacted with a compound of formula (XX):

$$Z(CH_2)mS(O)nW \qquad (XX)$$

wherein W, m and n are defined as above and Z represents halogen, to produce a compound of formula (XXI):



(XXI)

wherein R_3, R_4, X, P, W, m and n are defined as above, and the resulting compound of formula (XIX) is deprotected to produce a compound of formula (Ig).

10. A process for preparing a compound of formula (XX):

$$Z—(CH_2)mS(O)n—W \qquad (XX)$$

in which

W represents R_5 or 

,

R_5, R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5;

Z represents halogen

m denotes an integer of 2 to 15;

n denotes an integer of 0 to 2; and

p denotes an integer of 0 to 4,

characterized in that a compound of formula (XXII):

$Y(CH_2)mZ$ (XXII)

wherein Y represents halogen or hydroxy and Z and m are defined as above, is reacted with a compound of formula (XXIII):



(XXIII)

wherein W is defined as above, to produce a compound of formula (XXIV):

$Y(CH_2)m—S—W$ (XXIV)

wherein W, Y and m are defined as above; and the resulting compound of formula (XXIV) is then oxidized to produce the compound of formula (XX).

11. A process for preparing a compound of formula (XXVIII) or (XXIX):



(XXVIII)



(XXIX)

in which

 represents a single bond or a double bond;

R represents acyl or alkyl;

R_3 represents hydrogen, lower alkyl or halogeno lower alkyl, provided that

when ----- represents a double bond, R_3 is not present;

R_4 represents hydrogen or lower alkyl;

R_6 and R_7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or

R_6 and R_7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R_5;

X represents O, S or NR_8, wherein R_8 represents hydrogen or lower alkyl; and

m denotes an integer of 2 to 15,

characterized in that a compound of formula (XXV):



(XXV)

wherein R_3, R_4 and X are defined as above and P represents hydrogen or protected hydroxy group, is reacted with a compound of formula (XII):

$$Z—(CH_2)m—Y \qquad \text{(XII)}$$

wherein Z represents halogen, Y represents halogen or hydroxy and m is defined as above, to produce a compound of formula (XXVI):



(XXVI)

wherein R_3, R_4, X, P, Y and m are defined as above, the resulting compound of formula (XXVI) is reacted with a compound of formula (XVI):

(XVI)

wherein R_6 and R_7 are defined as above, to produce a compound of formula (XVVII):



(XXVII)

wherein R_3, R_4, R_6, R_7, X, P and m are defined as above, and the resulting compound of formula (XV) is deprotected to produce a compound of formula (XXVIII), or the resulting compound of formula (XXVIII) is esterified or alkylated to produce a compound of formula (XXIX).

12. A process for preparing a compound of formula (6):



(6)

characterized in that a compound of formula (1):



(1)

is reacted with oxalic acid diethyl ester and sodium hydride to produce a compound of formula (2):



(2)

the resulting compound of formula (2) is reacted with 3-methoxybenzenethiol represented by the formula:



to produce a compound of formula (3):



(3)

the resulting compound of formula (3) is reacted with hydrochloric acid to produce a compound of formula (4):



(4)

the compound of formula formula (4) is then cyclized to produce a compound of formula (5):



(5)

and the compound of formula (5) is reacted with methyl iodide in the presence of lithium diisopropylamide to produce the compound of formula (6).

13. An anti-estrogenic pharmaceutical composition containing the compound of formula (I) according to anyone of claims 1 to 5, as an active component.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 97/00265

A. CLASSIFICATION OF SUBJECT MATTER

IPC^6: C 07 D 311/30, 221/04, 335/06; A 61 K 31/35, 31/47, 31/38

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC^6: C 07 D 211/30, 221/04, 335/06

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DARC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Chemical Abstracts, Vol.110, No.17, 24 April 1989 (Columbus, Ohio, USA), page 718, column 2, abstract No.154253m, KUJUNDZIC, N. et al.:"Synthesis and antibacterial effect of derivatives of 5-(3,4,5-= trimethoxybenzyl)pyrimidine, -tetrahydropyrimidine, -hexahydropyrimidine and -hydantoin", & Croat. Chem. Acta 1988, 61(1), 121-35 (Eng).	1-13
A	US 4 904 661 A (PILGRIM et al.) 27 February 1990 (27.02.90), claims 1,7-9 (cited in the document).	1-13
A	WO 93/10 741 A2 (ENDORECHERCHE INC.) 10 June 1993 (10.06.93), claims 1-4,6 (cited in the document).	1-13

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
27 February 1998 (27.02.98)	24 March 1998 (24.03.98)
Name and mailing address of the ISA/ AT AUSTRIAN PATENT OFFICE Kohlmarkt 8-10 A-1014 Vienna Facsimile No. 1/53424/535	Authorized officer Brus Telephone No. 1/53424/519

Form PCT/ISA/210 (second sheet) (July 1992)

International application No.
PCT/KR 97/00265

Chemical Abstracts 110, 154253m
Synthesis and antibacterial effect of derivatives of 5-(3,4,5-trimethoxybenzyl)pyrimidine, -tetrahydropyrimidine, -hexahydropyrimidine and –hydantoin. In vitro antibacterial activity of these compounds was tested against some bacteria strains and compared with that of the well known bacteriostatic trimethoprim. The activity of the synthesized compounds was higher than that of trimethoprim against *Klebsiella pneumoniae* ATCC 10031 and *Pseudomonas aeruginosa* NCTC 10490 while the compounds acted also against *Corynebacterium xerosis* NCTC 9755, *E. coli* ATCC 10536 and *Shigella flexneri.*

US 4904661
Various antioestrogens are known. Two such compounds, tamoxifen and clomiphene, are commercially available, and others, for example nafoxidine, trioxifene and a number of compounds have been the subject of clinical trials. Now it was found, that certain phenol derivatives which are based on the hexoestrol nucleus but which bear an amidic or other function separated from the nucleus by an extended alkylene chain possess potent antioestrogenic activity.

WO 9310741
This invention relates to novel inhibitors of sex steroid activity such as antiestrogen compounds having effective antagonistic capability while substantially lacking agonistic effects. More particularly, certain preferred embodiments of the invention relate to certain estradiol and diphenylethylene analogs which have high affinity for estrogen receptors but do not activate such receptors and/or which inhibit the production of sex steroids or their precursors.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/KR 97/00265

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
US A 4904661	27-02-90	AT E 27953	15-07-87
		AU A1 27437/84	01-11-84
		AU B2 560583	09-04-87
		CA A1 1246566	13-12-88
		DE C0 3464364	30-07-87
		DK A0 2138/84	24-04-84
		DK A 2138/84	29-10-84
		EP A1 124369	07-11-84
		EP B1 124369	24-06-87
		ES A1 532012	16-12-85
		ES A1 544774	16-01-86
		ES A0 532012	16-01-86
		ES A5 544774	16-02-86
		ES A1 8603382	16-04-86
		ES A1 8604125	01-06-86
		FI A0 841648	29-04-84
		FI A 841648	29-10-84
		GB A0 8311678	02-06-83
		GR A 79913	31-10-84
		HU A2 [illegible]	28-02-85
		IE B 57239	17-06-92
		IL A0 71686	31-07-84
		IL A1 71686	30-11-87
		JP A2 59219256	10-12-84
		JP B4 4015778	19-03-92
		NO A 841687	29-10-84
		NO B 168526	25-11-91
		NO C 168526	04-03-92
		NZ A 207975	27-11-87
		PT A 78510	01-05-84
		PT B 78510	22-07-86
		US A 4733912	29-03-88
		US A 5021414	04-06-91
		ZA A 8403168	25-09-85
WO A2 9310741	10-06-93	AU A1 29393/92	28-06-93
		AU B2 681338	28-08-97
		EP A1 615448	21-09-94
		FI A0 942568	01-06-94
		FI A 942568	27-07-94
		IL A0 103941	13-05-93
		JP T2 7501528	16-02-95
		NO A0 942027	01-06-94
		NO A 942027	04-07-94
		NZ A 245359	26-01-96
		NZ A 272456	24-04-97
		US A 5595842	07-03-95
		WO A3 9310741	03-02-94
		ZA A 9209309	01-06-94
		US A 5686465	11-11-97
		AU A1 4[illegible]/89	03-05-90
		AU A1 [illegible]/93	05-08-93
		AU A1 24986/95	14-09-95
		AU B2 [illegible]	23-11-95
		AU B2 [illegible]	19-12-96
		CA A1 2001948	30-04-90
		EP A2 [illegible]	09-05-90
		EP A3 [illegible]	31-07-91
		HU A2 52114	28-06-90
		HU B 208150	30-08-93
		JP A2 [illegible]	27-09-90
		PT A 92168	31-05-90
		PT B 92168	03-07-95
		US A 5204337	20-04-93
		US A 5512249	30-05-97
		US A [illegible]	11-11-97
		US A [illegible]	28-02-95
		US A [illegible]	15-11-94
		US A [illegible]	17-12-96
		US A 5372996	13-12-94
		US A 5595985	21-01-97

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/KR 97/00265

AU	A1	58516/90	06-02-91
AU	A1	63425/94	21-07-94
AU	B2	665311	21-12-95
CA	AA	2062792	08-01-91
EP	A1	595796	11-05-94
HU	A0	9200048	29-06-92
HU	A2	60139	28-08-92
IL	A0	94991	10-06-91
JP	T2	4506799	26-11-92
NZ	A	234417	26-10-95
WO	A1	9100733	24-01-91
ZA	A	9005313	26-02-92
US	A	5593981	14-01-97
US	A	5610150	11-03-97
AU	A1	58545/90	06-02-91
AU	B2	643445	18-11-93
AU	A1	52174/93	10-02-94
AU	B2	668434	02-05-96
CA	AA	2062973	08-01-91
EP	A1	480950	22-04-92
HU	A0	9200047	29-06-92
HU	A2	60138	28-08-92
IL	A0	94990	10-06-91
IL	A1	94990	10-01-97
JP	T2	4506798	26-11-92
WO	A1	9100731	24-01-91
ZA	A	9005312	26-02-92